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INTRODUCTION 
“Foypdp jpahopdp njd;g jk;kf;fs; 
  koiyr; nrhy; Nfshjth;“. 
-  jpUf;Fws; 
 The pipe is sweet, the bite is sweet,” say those who have not heard the 
prattle of their own children. 
  “ngWktw;Ws; ahkwpt jpy;iy awptwpe;j  
  kf;fl;Ng wy;y gpw” 
-  jpUf;Fws; 
Among  all the benefits that may be acquired, we know no greater 
benefit than the acquisition of intelligent children. 
 The basic biological function of a living organism is its capacity to 
reproduce.  Among humans for every 80 married couples who produce 
children, there are 20 who are unable to have an offspring.  Approximately 
one-half of all cases can be traced to either partner. 
 In the fast pace of modern life, dietary habits, increasing prevalence of 
obesity, stress, smoking, contraceptives have all contributed to the decline in 
fertility. 
 In many southeast Asian Countries, infertility is considered a curse and 
the inability to conceive is often a stigma attached to the female partner 
though she may not always be the cause of it.   
 Approximately 15% of couples attempting their  first pregnancy meet 
with failure.  Most authorities define these patients as primarily infertile if they 
have been unable to achieve a pregnancy after one year of unprotected 
intercourse.  Conception normally is achieved within 12 months in 80 – 85% 
of couples who use no contraceptive measures and persons presenting after 
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this time should be therefore be regarded as possibly infertile and should be 
evaluated. 
AIM AND OBJECTIVES 
1. To  evaluate the therapeutic efficacy of  Siddha Drugs, Maladu 
Neenga Thailam and Saaravalli Mathirai in Penn Maladu (female 
infertlity) patients. 
2. To increase the fertility rate among the female infertility patients. 
3. To regularise the menstrual abnormalities 
4. To evaluate the toxicity & pharmacological actions in experimental 
animals 
5. To find out the adverse-effects of the drug in clinical trial, if any 
6. To have a complete study of the disease, Penn Maladu (Female 
Infertility) under the headings of 
a) Enn Vagai Thervugal 
b) Udal Kattugal 
c) Mukkutram etc. 
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ngz; kyL 
Foe;ijfisg; ngwhj jd;ikf;F ‘kyL’ vd;W ngah;. 
kyil 
1. Rj;j kyL 
2. fjyp kyL 
3. fhf kyL vd;W %tifahfg; gFj;Js;sdh; 
Rj;j kyL (Primary Infertility) 
 xU KiwahfpYk; fUj;jhpj;jNj fpilahj epiyikf;Fr; ‘Rj;j kyL’ vd;W ngah;. 
fjyp kyL (Secondary Infertility) 
 thio kuk; xU Kiw Fiy js;spaJk; kPz;Lk; Fiy js;shky; epd;WtpLk;.  
mJNghy; rpyh; xU kfit <d;W NkYk; fUj;jhpg;gNjapy;iy.  ,jw;Ff; ‘fjyp kyL’ 
vd;W ngah;. 
fhf kyL 
 fhfkhdJ ,uz;L ,dj;ijg; ngUf;fptpl;ljd;  Nghpy; kPz;Lk; jd; ,dj;ijg; 
ngUf;Ftjpy;iy.  mJNghy; kfspu; ,uz;Nl kfit <d;W NkYk; fUj;jhpg;gNjapy;iy.  
,jw;F ‘fhf kyL’ vd;W ngah;. 
 <jd;wpAk; fd;k kyL vd;W ehd;fhtjhf xd;iwAk; tFj;Js;sdh;. 
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fd;k kyL 
 #y; nfhs;;th;.  Mdhy; fUr;rpijT mbf;fb Vw;gl;L #y; fhyj;ij 
ePbf;fnthl;lhky; jLf;Fk; epiyf;F ‘fd;k kyL’ vd;W ngah;. 
fhuzq;fs; 
 kfspUf;F g+g;G epfo;T elg;gjhy; fUj;jhpf;fg;gLths; vd;W epue;jukhf 
nrhy;tjw;fpy;iy. 
(1) rpyUf;F fhkf;fpsh;r;rpapy;yhkNy g+g;G epfo;r;rp eilngWfpwJ.  
rpidg;igapy; ghprpid (Graffian Fallicle) Kjph;e;J rpid ntspg;gl;L 
tUtjpy;iy. 
(2) rpy Ntisfspy; fUg;igr; rspr;rt;T rpidiag; gjpaitf;fj; jbg;GWtjpy;iy. 
(3) kfsph;f;Ff; fUj;jhpg;gjpy; rpidg;gij kpfTk; gq;F nfhs;fpwJ.  
rpidg;igapd;W Rod;W ntspg;gl;l rpid (Ovum) FQ;rhe;jj;jhy; 
(Fimbriae) cwpQ;rg;gl;L> rpidg;ghijia milfpwJ. rpidg;ghijf; Foy;> 
rpidia fUg;ig miwia Nehf;fp ce;jr; nra;fpwJ.  ce;jpf; nfhz;Nl 
nry;Yk; rpid tpe;J mZf;fisr; re;jpj;Jf; fUf;nfhs;fpwJ.  MfNt> 
rpidg;ghij rpw;rpy Neha;fspy; jhgpjkile;J> Foypy; jpR tsh;r;rp 
Vw;gl;L> rpidAk;> tpe;JTk; re;jpf;f tha;g;gpy;yh fhuzj;jhy; kfsph; 
fUj;jhpg;gjpy;iy. 
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(4) rpy rkak; Gzh;r;rpapy; Vw;gl;l Nahdpf; frpT> fUg;ig Kff;frpT 
Mfpaitfs; tpe;J mZ caph; thoj;jf;fjhf ,y;yhtpl;lhy; fUg;ig .miwia 
miltjw;F Kd;Ng td;ikapoe;J kbe;J tpLfpd;wd. 
 (5) kfspUf;F gpwg;GWg;Gfspy; jhgpj Neha;fs; Vw;gl;bUe;jhYk; 
(6)       kfsph; gpwg;GWg;Gfs; rhptu Rfu;zhPjpahf ,y;yhikahYk; 
(7) fUg;ig Raepiyapy; ,y;yhky; khWgl;l epiyapy; ,Ue;jhYk;> 
(8) fUg;igapy; foiyf; fl;bfs; ,Ue;jhYk; fUj;jhpf;f Kbahky; kyl;Lj;jd;ik 
cz;lhFk;. 
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ngz; kyl;bd; Fzk; 
 jhNkjhd; khjhe;j UJ fhyj;jpy; 
  jf;fhd uj;jkJ rpte;J fhZk; 
 NtNkjhd; kQ;rs;epwq; fUikahFk; 
  tpidahd ePyepwQ; rPo;Ngh yhFk; 
 NghNkjhd; uj;jkJ TUz;il ahFk; 
  nghy;yhj ky %j;jpu epwNk ahFk; 
 ehNkjhd; nrhd;dgb rpfpr;rh rhuk; 
  ehl;LNshh;f; fwpantrd;W etpd;wpl; lhNu. 
- a+fpKdp 
kfspu; kUj;Jtk; 
nghUs; 
 khj khjk; epfo;TWfpd;w g+g;Gf; fhyq;fspy; Vw;gLk; g+g;Gf;frpT 
ed;F rpte;jpUj;jy;> kQ;rl;fUik epwkhfTk;> ePyepwr; rPo; NghyTk; 
rpw;rpW cUz;ilfshf ntspg;Nghe;jy;> NehAw;w fhyq;fspy; ,opAk; kyk;> 
rpWePh;fisnahj;jy; Nghd;w ,f;Fwp Fzq;fisg; ngw;wpUg;gjw;Fg; ngz; kyL 
vd;W ngah;. 
Meaning of the above: 
(i) Menstrual blood is bright red, yellowish black, and bluish red in 
colour. 
(ii) Menstrual blood is colloidal in consistency or like clots. 
(iii) Menstrual blood resembler motion and urine present in diseaced 
condition. 
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NOI VARUM VAZHIKAL (AETIOLOGY) 
I. ACCORDING TO MANMURUGIYAM 
 fUg;ig jd;dpy; tspepiwe; jpLjy; 
 fUf;Fopthapy; jirtsh;e; jilj;jy; 
 GOg;gy Njhd;wpf; fUTz; bLjy; 
 fUg;ig afj;Jg; ghrp gw;wy; 
 mjpy;nrq; FUjp fl;b epw;wy; 
 fUf;Fop kjh;j;jy; vDkpt;; thWk; 
 fUg;ig Aw;wpL Nehnad nkhopg. 
1. Amenorrhoea 
2. Any benign or malignant growths in the uterus like leiomyoma 
3. Infections of the genital tract like Pelvic Inflammatory Disease, 
genital tuberculosis 
4. Peritubal adhesions and adhesions within the uterus 
5. Blood stagnation within the uterus like adenomyosis 
6. Due to obesity in conditions like Polycystic Ovarian Disease, 
hypothyroidism. 
II. ACCORDING TO PARARASASEKARAM 
 jpwpky lhFk;thW nrd;kehl; Nlh\j; jhYk; 
 cWjpUg; g+j;jehsh nuhsph;nja;t tpNuhjj; jhYk; 
 nrwpAKj; Njh\j;jhYQ; rpNyl;Lk kpFjpahYk; 
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 kDTw kylh nkhd;W khjtdUr; nra;jhd;. 
 
1. Congenital malformations of the genital tract or congenital sex 
chromosomal abnormalities. 
2. Due to alterations in three humours. 
3. Increased Kapha humour. 
III. ACCORDING TO ATHMARAKSHAMIRDHAM VAIDHIYA 
SAARA SANGIRAHAM 
ghug;gh ngz;kylhq; fUg;gf; Nfhspd; 
gf;Ftj;ijr; nrhy;YfpNwd; gz;gha;f; NfS 
Mug;gh Mz;kyNl ahU ky;yhy; 
mg;gNd ngz;kyL ahU kpy;iy 
Neug;gh jtkpUe;Jk; nghUis aPe;Jk; 
Neuhf tpy;iyaJ #iy ahNy 
Ntug;gh NjtijNah Nlohq; fUg;gk; 
tphpj;J ed;wha; GfYfpNwd; tpUk;gpf;NfNs. 
 tsp epiwe; jpUg;gpd; GzUq; fhiyg; 
 ngz;zp Dlk;G typjU nkd;g 
 jir tsh;e; jpUg;gpd; neQ;R Fj;Jk; 
 GOf;fs; epuk;gpd; KJF NehFk; 
 ghrpg;gw;wpd; jiytyp Njhd;Wk; 
 FUjpfl;bd; nfz;il NehFk; 
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 fUf;Fop kjh;g;gpd; Vg;ge; Njhd;Wk; 
From the above verse, it is well known that the etiology of Maladu is 
same as mentioned in Manmurugium. 
IV. ACCORDING TO AGATHIYAR VAIDHYA KAVIYAM - 1500 
ghug;gh nfw;g fhyk; ghpTld; tha;T - Nja;T 
Nrug;gh Te;jpNahL nrd;wpLq; fUj;jhd; khSk; 
thug;ghGOj; jhZz;zpy; kynldr; nrhy;thug;gh 
Mug;gh tpjidg; Nghf;fpyhz; gps;is nrwpf;Fe;jhNd. 
• Increase in Vayu and Theyu elements. 
• Infections of the genital organs. 
CLASSIFICATION OF PENN MALADU 
I. According to YUGIMUNI CHIKITCHA SAARAM there are 3 types 
(i) Sudhtha Maladu 
(ii) Kathali Maladu 
(iii) Kaka Maladu 
II. According to JEEVA RAKSHAMIRTHAM ANUBAVA DEVA 
RAGASIUM & SARABENTHIRAR KARPA PINI  there are 4 types. 
(i) Athi Maladu 
(ii) Kathali Maladu 
(iii) Kaka Maladu 
(iv) Karuppa Maladu 
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III. According to MANMURUGIUM, there are 11 types 
 (i) Vali Maladu   (vii) Puzhu Maladu 
 (ii) Anal Maladu   (viii) Pettra Maladu 
 (iii) Iya Maladu   (ix) Mutru Maladu 
 (iv) Alagai  Maladu  (x) Noi Maladu 
(v) Varatchi Maladu  (xi) Seyarkai Maladu 
(vi) Karupai Maladu 
IV. According to ATHMARAKSHAMIRTHAM VAIDHYA SAARA  
 SANGIRAHAM.   
There are 7 types. 
(i) Vatha Maladu 
(ii) Pitha Maladu 
(iii) Alagai Maladu 
(iv) Petra Maladu 
(v) Varatchi Maladu 
(vi) Vayu Maladu 
(vii) Puzhi Mel Maladu 
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CLINICAL FEATURES 
A. ACCORDING TO YUGIMUNI CHIKITCHA SAARAM 
Athi Maladu -  epue;ju kyl;bd; Fzk; 
etpd;wplNt apLg;Gtapw; ngUj;Jf; fhZk; 
  eykhd NkdpaJ t+jpf; fhZk; 
 Ftpd;wplNt Kk;kbg;G tapw;wpy; Njhd;Wk; 
  Fztjpahe; Njtjh ngz;zh dhYk; 
 etpd;wplNt rd;kj;jd; kyNl ahFk; 
  rjhfhyq; fUg;gkJ jhpah njd;W 
 Gtpd;wplNt a+fpKdp rpfpr;rh rhuk; 
  Gfd;wpl;lhh; Nyhfj;J khe;jw; fhNk. 
nghUs;: clypd; kw;w ghfq;fis tpl ,Lg;Gk;> tapWk; ngUj;jpUj;jy;> cly; mijj;Jf; 
fhzy;> ce;jpapy; %d;W kbg;Gfs; fhZjy; Mfpa FwpFzq;fisf; nfhz;L vd;WNk 
fUj;jhpf;fhkypUf;Fk; jd;ikf;F epue;ju kyL vd;W ngah;. 
MEANING:   
 Obesity  
 Deposition of fat in the abdomen. 
Kathali Maladu – fjyp kyl;bd; Fzk; 
 etpyNt fd;dpah;fs; fjyp Nghyhk; 
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  ehl;lNt thiokuj; jhW Nghy 
 ftpyNt ike;jdhq; fUg;G nkhd;W 
  fhjypah sPd;wgpd; fUg;g kpy;iy 
 jtpyNt fUg;gFop kiwe;jJ Nkjhd; 
  jq;fpNa KOFehs; jilAz; lhFk; 
 GtpyNt a+fpKdp rpfpr;rh rhuk; 
  g+jyj;jpy; khdplw;Fg; g+l;b dhNu 
nghUs;: Fiy <d;w thio kWKiw Fiy <dhj;jd;ik Nghy kq;ifah;fs; xU Foe;ijia 
<d;w gpd;dh; fUg;igf; Fop nrayw;W g+g;Gj; jil Vw;gl;L> Gzh;r;rpAw;w NghJk; 
kWKiw fUjhpf;fhj jd;ikf;Ff; fjyp kyL vd;W ngah;. 
Meaning: After delivering a baby, woman attains menopause at or below 
the age of 40, (pre-mature menopause).  This is called Kathali Maladu. 
Kaka Maladu – fhf kyl;bd; Fzk; 
 MNkjhd; fhfj;jpd; kyNl ahFk; 
  mg;gNd fUg;igapy; Nrhhp nfl;L 
 NghNkjhd; fUg;igAe; Je;J Nkjhd; 
  Nghf;fhd fhAlNd fjL Nghyhk; 
 NtNkjh dpuz;L Ngh; ike;j Dz;lhk; 
  NtWtif fUg;gJ kyNl ahFk; 
 ehNkjhd; nrhd;dgb rpfpr;rh rhuk; 
  ehl;LNshh;f; fwpantd;W etpd;wpl;NlhNk. 
nghUs;: ,uz;L kfit <d;W fUg;igahdJ Nrhhp NfLw;w VJtpdhy; kWKiw 
fUj;jhpf;fhJ tpsq;Ffpd;w jd;ikf;Ff; fhf kyL vd;W ngah;. 
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B. ACCORDING TO JEEVARAKSHAMIRTHAM ANUBAVA 
DEVA RAGASIYAM, SARABENDRAR KARPAPINI 
 The  features of Athi, Kathali and Kaka Maladu are more or less same 
as described in Yugi Chikicha Saarum. And In addition, 
Karpa Maladu 
 Most of the women deliver a dead  foetus.  
C.  According to MANMURUGIYAM 
1. Vali Maladu: 
  ‘tsp kylhapd; nre;ePh;’ 
 In this type, the colour of the urine is red. 
2. Anal Maladu 
  ‘mdy; ky lhapd; kQ;rs; fiuj;njdr;  
rPWePh; hpwq;Fnkdr; nrg;Gth; Gyth;’ 
 In this type of infertility, the urine becomes bright yellow in colour. 
3. Iya  Maladu 
‘Ik;ky lhapd; rpWePh; kpfTk; 
ntSj;J Njhd;W nkd;gh; Gyth;’ 
 In this type, the urine becomes pale yellow in colour. 
4. Alagai Maladu 
  ‘g+g;gpd; fhiy tapw;wpl kUq;fpy; 
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NehT Njhd;wy; rpWePh; fLj;Jk; 
ntSj;Jq; fWj;JQ; rpte;J kpwq;fy; 
vDkpit ayif kyl;Lf; FwpNa’ 
 - There is pain in the lower abdomen during menstruation. 
 - Burning micturition  
 - The colour of the urine is pale yellow, red or black. 
5. Varatchi Maladu 
  ''cz;zpD Kly Kyu;e;J Nghjy; 
  kpf nfhl;lhtp - Njhd;wy; gw;gy 
  mr;rf; fdt}fs; Njhd;wy; vDkpit 
  twl;rp kyl;bd; Fwpnad nkhopg"" 
• Weight loss 
• Intractable yawning 
• Experiences dreadful dreams often. 
6. Karupai Maladu 
  ‘tapW nghUky; czt whik 
Vg;ge; Njhd;wy; fUf;Fop Rw;wp 
tspepd; wpLjy; vDkpit fUg;ig 
tspkyl;bd; Fwp ahnkd nkhopg’ 
Signs and Symptoms 
¾ Flatulence 
¾ Loss of Appetite 
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¾ Belching 
¾ Menstrual irregularities like oligomenorrhoea, hypomenorrhoea, 
amenorrhoea 
 
7. Puzhu Maladu 
  ‘kWg;G Njhd;wy; jpq;fs; tUKOf; 
  ,uz;nlhU jpq;f spilap YWjy; 
  clyk; ntSj;jy; Fwpjpd TWjy; 
  ,itGO kyl;Lf; Fwpnad nkhopg 
 fUg;ig apw;GO kpf;fpL khapd; 
 tapw;wb Fj;Jk; jpq;fl; g+g;Gj; 
 jirfOePh; Nghy; Njhd;Wk; Gzh;r;rpapy; 
 mopjU ePUw; whil fiwg;gLk;’ 
Signs and Symptoms 
 Dysfunctional  uterine bleeding 
 Pallor 
 Pruritis vulva  
 Intense pain  in the lower abdomen 
 The colour of the meustrual blood is like that of the water washed out 
from the meat 
 Excessive vaginal discharge after coitus. 
8. Pettra Maladu 
  ‘clyk; gUj;jy; ntk;gy; Nehjy; 
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fOePh; Nghyr; rpWeP hpwq;fy; 
iffh nyhpjy; vDkpit nay;yhk; 
ngw;w kyl;bd; Fwpnad nkhopg’ 
 
Signs and Symptoms 
 Obesity 
 Burning Micturition 
 Burning sensation in the extremities 
 The colour of the urine is like the water washed out from the rice. 
9. Mutru Maladu 
  ‘kUe;jp Dk;gpw newpapD ePq;fh 
kyL Kw;W kynld nkhopg’ 
 In this type, there is no improvement even on treatment. 
10. Noi Maladu 
  ‘Nehapd; tUtJ Neha;ky lhFk; 
tspKjw; gygpzp te;Jw khapDk; 
fUf;fha; fUf;fs; jhuh thapDk; 
ngz;ghy; Neha;ky nlhd;wpLk; nkd;g’ 
 Chronic illnesses like endocrinal disorders (Hypothroidism), renal and 
cardiac diseases lead to Infertility in females. 
11. Seyarkai Maladu 
 ‘fUq;Nfh Sg;gpidf; fisj yhYk; 
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mWitapd; njhopYwr; nra;j yhYk; 
kUe;jpw; fUTwr; nra;j yhYk; 
vd;Wk; Gzuh jpUj;j yhYk; 
fUf;Nfh spy;tif Gzh;j yhYk; 
nraw;if kyL kUtpl apay;Ng’ 
 Surgical sterilization in the female or previous surgery in the abdomen 
leads to adhesions 
 Taking contraceptives to avoid pregnancy 
 Avoiding sexual intercourse 
 Sexual intercourse during first trimester. 
D. ACCORDING TO ATHMARAKSHAMIRTHAM 
 The clinical features described in Athmarakshamirtham are same as in 
Manmurugium. 
E. ACCORDING TO SARABENDRAR KARPA PINI 
a) Karpa Sayu Puralal          
 ‘Xjpa khkf tpy;yJ ePjpAiue;jpL Ntd;wpUNt 
 jhJFky; FypNy kyUz;lJ jhz;ilNa Guspy; 
 ePjpajha; tpOkh tKjy; Gfepd;wplkq; nfhUTk; 
 NtjKkpg;gbNa AiuahbL nkd;nfhb ePawpNa’ 
The position of the uterus may be abnormal and it may be retroverted . 
Signs:               
‘Nkypdp kq;ifah; khjtplhnad tpyfpa ehyhehs; 
thypg thlth; $ba Nghjpdpd; kq;if tpyhtJjhd; 
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NtypL Gz;nzdNt typAz;nldpd; nkd;gfkh kyUq; 
Nfhy kpyhJGuz;lJ ntd;wwp $wtdTljhNk’ 
From the above verse, it is known that women with Karpasayu Puralal 
experiences pain along the ribs during coitus on the  fourth day of mensturation. 
 
b) Vayu Seruthal 
 “ePawpkhlyh; jhdjpy; tha;ThpNdak ehkKje; 
 jhafkhfpa khlydw;wpjpd; rhunkyh nkhopfpr; 
 rPnad ePnudNtaJNgha; tsh; Njfnky;yhk; typah 
 NahAk; tpjq;fspjhF kwpe;J nfhsnshz;nlhbapd;GwNt” 
Since there is excessive vayu within the uterus, it reduces the virulence 
of the sperm and make it dead. 
Signs: 
 cz;lhNk jpuz;BhpU ehspdpnyhz; fztd; Gzuj; 
 jz;lhh; Njfnkyhk; typnad;dpw; wq;fpa gfkyh;e;j 
 gz;lhh; thA ciwe;J ntd;wwp...... 
In this type,  the woman experiences pain all over the body during 
coitus on fourth day of menstruation. 
c) Thasai Seruthal 
 ,d;GW khkyh; jd;dpYNk jir Nafkjha; tsu 
md;GWkg; nghONj tpOkhtKjQ; rsp NghYUfp 
td;gbah JiwahJ fyq;fp tope;jpLNk ntspapy; 
nkd;gj Ehypil fQ;rkjh Ky;nkd; Fod; nky;ypaNy 
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Benign or malignant growth in the uterus interrupts the passage of the 
semen. 
Signs 
 ........ khjpil jhd; typfhZnkdpw; 
fhj;jpu ty;FypNy jirnad;w wpfspub gpd;dKe;..... 
There is pain in the groin or hip region during coitus. 
d) Ushnathikam 
nky;ypjo; g+tpdpy; ty;typAl;bz nkd; NkYz;lhfpy; 
ey;ypjkha; tpOnkd;dKje; jz;dhba ntz;nzajhk;  
nfhy;yjp dpd;W kpFe;J ntJk;gpf; NfhKfkhk; topNa 
nry;y Khpj;Jiw Ngha;tpL khkiwr; r+j;jpukpg;gbNa 
Any inflammatory condition of the vagina, uterus or fallopian tubes 
destroy the sperm. 
Signs 
 Njd;nkhopiag; Gzh; NghjpdpNy Jil Nrh;e;J typf;Fnkdp;d;  
khd;kyh; jhdjpYl;bz nkd;w khl;L ntd;Gq; 
In this type, there is pain in both thighs during coitus. 
e) Seethala Serkai 
,g;gbg; g+tpd;w rPjsNk Awpdd; gkjhk; Ntisr; 
nrg;gpa khtKjk; tpoepd;W njspe;J Kwpe;JlNd 
mg;Gntdg; gOjhfp eidae;jaNyhb aope;JtpLk; 
ikg;gbAq; Fow; nrg;gps nkd;;Kiy ty;yped; thZjNy 
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In kapha diseases like pyogenic infections and genital tuberculosis, it 
destroys the sperms. 
Signs: 
....................... ePq;fpL khh;gjpNy 
fz;z typf;Fnkdpd; kyh;jhdjpw; fhz;gJ rPjsnkd; 
nwz;zp kUe;Jfs; nra;jpL nrg;GtNdh FoNye;jpioNa 
In this type, there is pain in the chest region during coitus. 
 
f) Puzhu Undathal 
thddp NahdpapNy kyh;kPjpdpd; khGOtq; FwpNyh 
Czpa khtKje; jidNanaLj; Jz;L fspj;Jkpf 
Mztkhf epiyj;J tsh;e;jpL khifapdhd; kfitf;  
fhzpia nad;W fiue;jpL thhpJ fz;lwp fhhpifNa. 
nghUs;: Nahdp kw;Wk; ngz; ,dTWg;Gfspy; fpUkpfspd; jhf;fj;jhy; 
kfT mope;J tply;. 
Signs: 
....... khjiu kUtpa NghjpdpNa 
rpj;j kfpo;r;rp nfhshkY Nkikay; jPh;f;fpiy nad;Wnrhypy; 
tpj;jf ty;FypNy GOntd;wwp 
In this type, there is no orgasm. 
g) Sanka Thosam 
fhhpifapd; Fwpkh kyh; Nkd;kpF fhw;nwDQ; rq;ifawpy; 
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tPhpaNk tpOk; NghjpNyaJ tPo;tjpd; Kd;ghfr; 
rhunkyhq; nfhLNgha; tpLNkapJ rj;jpaNk Aiuj;Njhk; 
thuzp nfhq;if ey;yhapij ePawp khkiw Ehz; KiwNa 
nghUs;: fhw;W vd;Dk; rq;if Njh\j;jhy; ngz; ,dTWg;Gfs; 
ghjpf;fg;gLtjhy; Vw;gLtJ. 
Signs: 
ehafpNahL wthifapw; Fjpfhduk; gpOj;jpL nkd;whw; 
wPPaJw; rq;iffshkJ ntd;wwp Nrahp tpopkhNj 
In this type, there is pain in calf muscles during coitus.  
h) Avaya Ettra Thazhvugal 
Ehypilahs; FwpahokjhfT Ehy; nfhO ed; Fwpjhd; 
rPyKld; rhpePs kpyhtpow;Nwa; tjpdhy Kjk; 
nghydNt AiwahkYld;gpw; gue;J fye;JtpLk; 
NtnyDik tpopahapJ fz;lwpNtjd; tpjpg;gbNa 
Congenital elongation of the cervix, acute retroverted uterus, septate 
vagina, transverse vaginal septum are the anatomic defects that result 
in infertility. 
i) Poorva Vinai 
kq;ifauhapD kltuhapD khtpidah tpo;jQ; 
rq;ifapy kyUe;jpajhYld; jq;fpa ntg;gkjhw; 
nghq;fpa khtKjQ; rykhfp kpFe;J nghope;J tpLk; 
,q;fpJ ePjpawpe;jpL Ntjkpirj;j jpsq;nfhbNa 
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In this type, due to kanma vinai or excessive usage of medications, 
their sperm or ovum becomes inactive.  
COMPLICATIONS: 
1. Malattu Vali 
kyl;L Neha;fs; kUtp kpFjypd; 
fUg;igapy; typgy Njhd;wp Kjph;e;J 
tpyf;fpd; fhiy tFj;j kpUf;Fk;  
On the days of menstruation, very severe dysmenorrhoea is present. 
 
2. Malattu Janni 
tpyf;fpd; fhiyg; Gspj;jiy Az;zy; 
kpfT Kz;zy; cz;l jwhik 
kpfFsp Nuw;wy; Kjypa gpwTk; 
kyb jdf;Fk; fyitg; gpzp jUk;. 
On the days of menstruation, if rotten foods or excessive foods are 
taken or indigestion is present, it leads to Malattu Janni. 
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MODERN ASPECT 
INFERTILITY 
 Infertility is defined as a failure to conceive within one or more years of 
regular unprotected coitus. 
 Primary infertility denotes those patients who have never conceived. 
Secondary infertility indicates previous pregnancy but failure to conceive 
subsequently. 
 80 percent of the couples achieve conception if they so desire, within 
one year of having regular intercourse with adequate frequency (4-5 times a 
week).  Another 10 percent will achieve the objective by the end of second 
year.  As such 10 percent remain infertile by the end of second year. 
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 The relative prevalence of the etiologies of infertility is 
 Male factor   - 30 – 40% 
 Female Factor  - 40 – 50% 
 Both   - 10% 
 An association between the age of woman and reduced fecundability 
has been well documented.  This decline begins in the early thirties and 
accelerates in the late thirties and early forties. 
 
 
FEMALE INFERTILITY 
The female  factor contribute to 40 – 50% of infertility. 
The important causes of female infertility as given by FIGO manual (1990) 
are,  
- Tubal and peritoneal factors -  25 – 35% 
- Ovulatory factor    - 15 – 25% 
- Endometriosis   - 1 – 10% 
ETIOLOGY 
OVARIAN FACTORS 
 The ovulatory dysfunctions encompass: 
 Anovulation or oligo – ovulation 
 Luteal phase defect (LPD) 
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 Luteinised unruptured follicle. 
TUBAL FACTORS 
The  impaired tubal function includes, 
 Defective ovum pick up 
 Impaired tubal motility 
 Loss of cilia 
 Partial to complete obstruction of the tubal lumen 
The impaired function of above anyone is related to , 
 
 Tubal infection (or) 
 Peritubal adhesions following pelvic surgery or infection or 
endometriosis. 
PERITONEAL FACTORS: 
 In addition to peritubal adhesions, even minimal endometriosis may 
produced infertility. 
UTERINE FACTORS 
 Uterine Hypoplasia 
 Inadequate secretry enclometrium 
 Fibroid uterus 
 Endometritis (tubercular in particular) 
 Uterine synechiae 
 Congenital malformation of uterus 
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CERVICAL FACTORS 
Anatomic : Anatomic defects preventing sperm ascent  
 Congenital elongation of the cervix, 
 Second degree uterine prolapse 
 Acute retroverted uterus 
 Pin hole os 
 Cervical canal occluded by a polyp. 
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Physiologic 
 The fault lies in the composition of the cervical mucus, so much that 
the spermatozoa fail to penetrate the mucus. The mucus may be, 
 Scanty – following amputation ionisation or deep cauterisation of the 
cervix. 
 Excessive, purulent – chronic cervicitis. 
 Presence of Antisperm antibodies or sperm immobilizing antibodies. 
VAGINAL FACTORS 
 Atresia Vagina (Partial or Complete) 
 Transverse vaginal septum 
 Septate vagina 
 Narrow introitus. 
IMMUNOLOGICAL FACTOR 
               and 
GENERAL FACTORS 
 Advanced age of the woman beyond 35 is related to infertility 
 Use of lubricants during intercourse which may be spermicidal 
 Anxiety and apprehension 
 Infrequent intercourse, lact of knowledge of coital technique and timing 
of coitus to utilize the fertile period are very much common even 
amongst the literate couples. 
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ANOVULATORY INFERTILITY 
 The ovarian activity is totally dependant on the gonadotrophins and the 
normal secretion of gonadotrophins depends on the pulsatile release of GnRH 
from hypothalamus. 
 As such, ovarian dysfunction is likely  to be linked with disturbed 
hypothalamo pituitary ovarian axis either primary or secondary from thyroid or 
adrenal dysfunction. 
 Thus, the disturbance may result not only in anovulation but may also 
produce oligomenorrhoea or even amenorrhoea.  Anovulatory cycles usually 
represent a lesser degree of disturbance with these normal pathways than 
does amenorrhoea. 
 As there is no ovulation, there is no corpus luteum formation.  In the 
absence of progesterone, there is no secretary endometrium in the second 
half of the cycle. 
POSSIBLE CAUSES OF ANOVULATION 
 Any disturbance in hypothalamo – pituitary – ovarian action will result 
in anovulation. 
DISTURBANCE AT THE LEVEL OF HYPOTHALAMUS 
1. Obesity or weight loss 
2. Psychologic disturbances 
3. Psychotrophic drugs 
4. Tranquilizers, oral pill 
 29
DISTURBANCE AT THE LEVEL OF PITUITARY 
Primary Causes 
1. Sheehan’s syndrome 
2. Tumour – Prolactinoma 
Secondary Causes 
1. Hypo or Hyperthoroidism 
2. Adrenal Hyperplasia 
DISTURBANCES AT THE LEVEL OF OVARY 
1. Polycystic ovarian disease (PCOD) 
2. Premature ovarian failure 
3. Luteinised unruptured follicles 
4. Endocrinopathy. 
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CHRONIC ANVOULATION 
 At least 80% or more of gynecologic endocrine disorders result from 
chronic anovulation. Women with chronic anovulation fail to ovulate 
spontaneously but may ovulate with appropriate therapy.  The ovaries of such 
women do not secrete estrogen in a normally cyclic pattern.   It is clinically 
useful to differentiate those women who produce enough estrogen to have 
withdrawal bleeding after progestogen therapy from those who do not; the 
latter often have hypothalamic – pituitary dysfunction. 
CHRONIC ANOVULATION WITH ESTROGEN PRESENT 
 This disorder is most commonly caused by polycytic ovarian syndrome. 
Chronic anovulation  with estrogen present may also occure with tumors of 
the ovary.  These include granulosa – theca cell tumors, Brenner tumors, 
cystic teratomas, mucous cystadenomas, and Krukenberg tumors.  Such 
tumors can either secrete excess estrogen themselves or produce androgens 
that are aromatized in extraglandular sites.  Chronic anovulation and the 
clinical features of PCOS result.  Occasionally, areas of the ovary not involved 
with tumors show the characteristic histologic changes of PCOS.  Other 
causes of chronic anovulation with estrogen present include adrenal 
production of excess androgen, (usually adult-onset adrenal hyperplasia due 
to partial 21-hydrozylase deficiency) and hypothyroidism. 
CHRONIC ANOVULATION WITH ESTROGEN ABSENT 
 Women with chronic anovulation  who have low or absent estrogen 
production and do not experience withdrawal bleeding after progestogen 
treatment usually have hypogonadotropic hypogonadism due to disease of 
either the pituitary or the central nervous system. 
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 Isolated hypogonadotropic hypogonadism associated with defects of 
smell (olfactory bulb defects) is known as the Kallmann syndrome, which is 
due to a single gene defect in the X-linked KAL gene.  Affected women are 
sexually infantile and have a defect in the synthesis and/or release of GnRH.   
Hypothalamic lesions that impair GnRH production and cause 
hypogonadotropic hypogonadism include crainopharyngioma, germinoma 
(pinealoma), glioma, Hand-Schuller-Christian disease, teratoma, endodermal-
sinus tumors, tuberculosis, sarcoidosis, and metastatic tumors that cause 
suppression or destruction of the hypothalamus.  Central nervous system 
trauma and irradiation can also cause hypothalamic amenorrhea and 
deficiencies in secretion of growth hormone, adrenocorticotropic hormone 
(ACTH), vasopressin, and thyroid hormone.  Rare, autosomal recessive 
defects in the GnRH receptor have also been described. 
 More commonly, gonadotropin deficiency leading to chronic 
anovulation is believed to arise from functional disorders of the hypothalamus 
or higher centers.  A history of a stressful event in a young woman is frequent.  
Gonadotropin and estrogen levels are in the low to low-normal range as 
compared with normal women in the early follicular phase of the cycle.  In 
addition, rigorous exercise, such as jogging or ballet, and diets that result in 
excessive weight loss may lead to chronic anovulation, particularly in girls with 
a history of prior menstrual irregularity.  The amenorrhea in these women 
does not appear to be a result of weight loss alone but a combination of a 
decrease in body fat and chronic stress.  An extreme form of weight loss with 
chronic anovulation occurs in anorexia nervosa.  In anorexia nervosa 
amenorrhea can precede, follow, or coincide with weight loss. 
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 In addition, chronic debilitating disease such as end-stage kidney 
disease, malignancy, inflammatory bowel disease, and malabsorption can 
lead to hypogonadotropic hypogonadism via hypothalamic mechanism. 
 Treatment of chronic anovulation due to hypothalamic disorders 
includes ameliorating the stressful situation, decreasing exercise, and 
correcting weight loss, as appropriate.  These women are susceptible to the 
development of osteoporosis; estrogen replacement therapy is recommended 
to induce and maintain normal secondary sexual characteristics and prevent 
bone loss in those who do not desire pregnancy, and gonadotropin or 
gonadorelin therapy is indicated when pregnancy is desired.  When 
appropriate, therapy is directed at the primary disease of the hypothalamus. 
 Disorders of the pituitary can lead to the estrogen-deficient form of 
chronic anovulation by at least two mechanisms – direct interference with 
gonadotropin secretion by lesions that either obliterate or interfere with the 
gonadotrope cells (chromophobe adenomas, Sheehan’s syndrome) or 
inhibition of gonadotropin secretion in association with excess prolactin 
(prolactinoma).  Pituitary tumors may secrete no hormone, one hormone, or 
more than one hormone.  Prolactin levels are elevated in 50 to 70% of 
patients with pituitary tumors, either because of prolactin secretion by the 
tumor itself (in the case of prolactinomas) or because the tumor mass 
interferes with the normal hypothalamic inhibition of prolactin secretion. 
 Prolactin excess associated with low levels of LH and FSH constitutes 
a specific subtype of hypogonadotropic hypogonadism.  One-tenth or more of 
amenorrheic women have increased levles of prolactin, and more than half of 
women with both galactorrhea and amenorrhea have elevated prolactin 
levels.  The amenorrhea is most often associated with decreased or absent 
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estrogen production, but prolactin-secreting tumors on occasion are 
associated with normal ovulatory menses or chronic anovulation with estrogen 
present.  In the latter half of pregnancy, prolactin-secreting pituitary tumors 
may expand, leading to headache, compression of the optic chiasm, 
bitemporal hemianopia, and blindness.  Therefore, before inducing ovulation 
for the purposes of achieving pregnancy, it is mandatory to exclude the 
presence of a pituitary tumor. 
 Large pituitary tumors such as null cell adenomas—whether or not 
hyper-prolactinemia is present—are likely to be associated with deficiency of 
hormones in addition to gonadotropins. 
 Craniopharyngiomas, which are thought to arise from remnants of 
Rathke’s pouch, occur most frequently in the second decade of life and often 
extend into the suprasellar region.  Many of these tumors calcify and can be 
diagnosed by conventional skull film or CT.  Patients often present with sexual 
infantilism, delayed puberty, and amenorrhea due to gonadotropin deficiency; 
secretion of TSH, ACTH, growth hormone, and vasopression may also be 
impaired. 
 Panhypopituitarism can be caused by mutations in transcription 
factors (Pit-1; Prop-1) involved in pituitary gland development, result 
from surgical or radiation treatment of pituitary adenomas, or develop 
after postpartum hemorrhage (Sheehan’s syndrome). 
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THE OVARIAN CYCLE 
 Within the ovary, the menstrual cycle can be divided into three phases: 
 The follicular phase 
 Ovulation 
 The luteal phase 
FOLLICULAR PHASE 
 The development of the oocyte is the key event in the follicular phase 
of the menstrual cycle.   The ovary contains thousands of primordial follicles 
that are in a continuous state of development from birth, through periods of 
anovulation, such as pregnancy, to the menopause.    These initial stages of 
follicular development are independent of hormonal stimulation.  In the 
absence of the correct hormonal stimulus however, follicular development 
fails at the preantral stage,  with ensuing follicular atresia.  Development 
beyond the preantral stage is stimulated by the pituitary hormones, (luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH)) which can be 
considered as key regulators of oocyte development. 
 At the start of the menstrual cycle, FSH levels begin to rise as the 
pituitary is released from the negative feedback effects of progesterone, 
oestrogen and inhibin.  Rising FSH levels rescue a cohort of follicles from 
atresia, and initiate steroidogenesis.   
Steroidogenesis 
 The basis of hormonal activity in preantral to pre-ovulatory follicles is 
described as the ‘two cell, two gonadotrophin’ hypothesis.  Steroidogenesis is 
compartmentalized in the two cell types within the follicle:  the theca and 
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granulosa cells.  The two cell, two gonadotrophin hypothesis states that these 
cells are responsive to the gonadotrophins, LH and FSH respectively. 
 Within the theca cells, LH stimulates the production of androgens from 
cholesterol.  Within granulosa cells, FSH stimulates the conversion of thecally 
derived androgens to oestrogens (aromatization).  In addition to its effects on 
aromatization, FSH is also responsible for proliferation of granulosa cells.  
Although other mediators are now known to be important in follicular 
development, this hypothesis is still the cornerstone to understanding events 
in the ovarian follicle.  The respective roles of FSH and LH in follicular 
development are evidenced by studies on women undergoing ovulation 
induction in whom endogenous gonadotrophin production has been 
suppressed.  If pure FSH alone is used for ovulation induction, an ovulatory 
follicle can be produced but oestrogen production is markedly reduced.  Both 
FSH and LH are required to generate a normal cycle with adequate amounts 
of oestrogen. 
 Androgen production within the follicle may also regulate development 
of the preantral follicle.  Low levels of androgens enhance aromatization and 
therefore increase oestrogen production.  In contract, high androgen levels 
inhibit aromatization and produce follicular atresia.  A delicate balance of FSH 
and LH is required for early follicular development.  The ideal situation for the 
initial stages of follicular development is low LH levels and high FSH levels, as 
seen in the early menstrual cycle.  If LH levels are too high, theca cells 
produce large amounts of androgens causing follicular atresia. 
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Selection of the Dominant Follicle 
 The developing follicle grows and produces steroid hormones under 
the influence of the gonadotrophins LH and FSH.  These gonadotrophins 
rescue a cohort of preantral follicles from atresia.  However, normally only one 
of these follicles is destined to grow to a pre-ovulatory follicle and be released 
at ovulation the dominant follicle. 
 The selection of the dominant follicle is the result of complex signalling 
between the ovary and the pituitary.  In simplistic terms, the dominant follicle 
is the largest and most developed follicle in the ovary at the mid-follicular 
phase.  Such a follicle has the most efficient aromatase activity and the 
highest concentration of FSH – induced LH receptors.  The dominant follicle 
therefore produces the greatest amount of oestradiol and inhibin.  Inhibin 
further amplifies LH-induced androgen synthesis, which is used as a substrate 
for oestradiol synthesis.  These features mean that the largest follicle 
therefore requires the lowest levels of FSH (and LH) for continued 
development.  At the time of follicle selection, FSH levels are declining in 
response to the negative feedback effects of oestrogen.  The dominant follicle 
is therefore the only follicle that is capable of continued development in the 
face of falling FSH levels. 
 Ovarian-pituitary interaction is crucial to the selection of the dominant 
follicle, and the forced atresia of the remaining follicles. When this interaction 
is bypassed, as in ovulation induction with the administration of exogenous 
gonadotrophins, many follicles continue to develop and are released at 
ovulation with an ensuing multiple gestation rate of around 30 per cent.  
During in vitro fertilization (IVF) the production of many ovulatory follicles is 
desired since the oocytes are harvested, and fertilized in vitro, and the 
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number of embryos replaced can be carefully controlled.  However, if such 
multiple follicular development occurred unchecked in the normal cycle, it 
would lead to the production of multiple gestations of high-order numbers, 
with their associated problems. 
Inhibin and Activin 
 Although folliculogenesis, ovulation and the production of progesterone 
from the corpus luteum can be explained largely in terms of the interaction 
between pituitary gonadotrophins and sex steroids, it is becoming clear that other 
autocrine or paracrine mediators also pay a role.  One of the most important of 
these is inhibin. 
 Inhibin was originally described as a testicular product that inhibited 
pituitary FSH production, hence its name.  However, inhibin is also produced 
by a variety of other cell types, including granulosa cells within the ovary.  
Granulosa cell inhibin production is stimulated by FSH but in women, as in 
men, inhibin attenuates FSH production.  Within the ovary, inhibin enhances 
LH – induced androgen synthesis.  The production of inhibin is a further 
mechanism by which FSH levels are reduced below a threshold at which only 
the dominant follicle can respond, ensuring atresia of the remaining follicles. 
 Activin is a peptide that is structurally related to inhibin.  It is produced 
both by the granulosa cells of antral follicles, and also by the pituitary gland.  
The action of activin is almost directly opposite to that of inhibin in that it 
augments pituitary FSH secretion, and increases FSH binding to granulosa 
cells.  Granulosa cell activin production therefore appears to amplify the 
effects of FSH within the ovarian follicle. 
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Insulin-like Growth Factors 
 Insulin-like growth factors (IGF-I and IGP-II) act as paracrine 
regulators. Circulating levels do not change during the menstrucal cycle, but 
follicular fluid levels increase towards ovulation, with the highest level found in 
the dominant follicle.  The actions of IGF-I and – II are modified by  their 
binding proteins; insulin-like growth factor binding proteins (IGFBPs).  
 In the follicular phase, IGF-I is produced by theca cells under the action 
of LH. IGF-I receptors are present on both theca and granulosa cells. Within 
the theca IGF-I  augments LH induced steroidogenesis. In granulosa cells, 
IGF-I augments the stimulatory effects of FSH on mitosis, aromatase activity 
and inhibin production. In the preovulatory follicle,  IGF-I enhances LH-
induced progesterone production form granuloss cells. Following ovulation, 
IGF-II is produced from luteinized granulosa cells, and acts in an autocrine 
manner to augment LH-induced proliferation of granulosa cells.  
OVULATION 
 Late in the follicular phase, FSH induces LH receptors on granulosa 
cells. Oestrogen is an obligatory co-factor in this effect. As the dominant 
follicle develops further, follicular oestrogen production increases. The 
production of oestrogen is eventually sufficient that the threshold required for 
oestrogen to exert a positive feedback effect on pituitary LH secretion is 
achieved. Once this occurr, LH levels increase, at first quite slowly (day 8 to 
day 12 of the menstrual cycle) and then more rapidly (day 12 onwards.) 
During this time, LH induces luteinization of granulosa cells in the dominant 
follicle, so that progesterone is produced. Progesterone further amplifies the 
positive feedback effect of oestrogen on pituitary LH secretion, leading to a 
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surge of LH, Ovulation occurs 36 hours after the onset of the LH surge. The 
LH surge is one of the best methods by which the time of ovulation can be 
determined, and is the event detected by most over-the-counter ‘ovulation 
predictor’ kits.  
 The periovulatory FSH surge is probably induced by the positive 
feedback effects of progesterone. In addition to the rise in LH, FSH and 
oestrogen that occur around ovulations, a rise in serum androgen levels also 
occurs. These androgens are derived from the stimulatory effect of LH on 
theca cells, particularly those of the non-dominant follicle. This rise in 
androgens may have an important physiological effect in the stimulation of 
libido, ensuring that sexual activity is likely to occur at the time of ovulation 
when the woman is at her most fertile.  
 Prior to the release of the oocyte at the time of ovulation, the LH surge 
stimulates the resumption of meiosis, a process which is completed after the 
sperm enters the egg. In order for the ovary to release the oocyte at ovulation, 
breakdown of the follicular wall is required. This event is coordinated by LH, 
TSH and progesterone which stimulate the activity of proteolytic enzymes 
such as plasminogen activators (which produce plasmin, which stimulates 
collagenase activity) and prostaglandins. Prostaglandins not only stimuate the 
activity of proteolytic enzymes, but also promote an inflammatory-type 
response within the follicle wall, and by stimulation of smooth muscle activity 
may help extrusion of the oocyte.  
 The crucial importance of prostaglandins and other eicosanoids in the 
process of ovulation is demonstrated by studies showing that inhibition of 
prostaglandin production may result in failure of release of the oocyte from the 
ovary, despite apparently normal steroidogenesis (the luteinized unruptured 
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follicle syndrome, LUF). Although LUF appears to be an uncommon cause of 
infertility, women wishing to become pregnant should be advised to avoid 
taking prostaglandin synthetase inhibitors such as aspirin and ibuprofen which 
may inhibit oocyte release.  
LUTEAL PHASE 
 The luteal phase is characterized by the production of progesterone 
from the corpus luteum within the ovary.  The corpus luteum is derived both 
from the granulosa cells that remain after ovulation, and from some of the 
theca cells which differentiate to become theca lutein cells.  The graunlosa 
cells of the corpus luteum have a vacuolated appearance associated with the 
accumulation of a yellow pigment, lutein from where the corpus luteum 
derives its name.  Extensive vascularization within the corpus luteum ensures 
that the granulosa cells have a rich blood supply providing the precursors for 
steroidogenesis. 
 The production of progesterone from the corpus luteum is dependent 
on continued pituitary LH secretion.  However, serum levels of progesterone 
are such that LH and FSH production is relatively suppressed.  This effect is 
amplified by moderate levels of oestradiol and inhibin that are also produced 
by the corpus luteum.  The low levels of gonadotrophins mean that the 
initiation of new follicular growth is inhibited for the duration of the luteal 
phase. 
Luetolysis 
 The duration of the luteal phase is fairly constant, being around 14 
days in most women.  In the absence of pregnancy and the production of 
human chorionic gonadotrophin (hCG) from the implanting embryo, the 
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corpus luteum regresses at the end of the luteal phase, a process known as 
luteolysis.  The control of luteolysis in women remains obscure.  As the 
corpus luteum dies, oestrogen, progesterone and inhibin levels decline.  The 
pituitary is released from the negative feedback effects of these hormones 
and gonadatrophins, particularly FSH, start to rise.  A cohort of follicles which 
happen to be at the preantral phase are rescued from atresia and a further 
menstrual cycle is initiated. 
SUMMARY OF OVARIAN EVENTS 
FOLLICULAR PHASE 
 LH stimulates theca cells to produce androgens. 
 FSH stimulates granulosa cells to produce oestrogens. 
 The most advanced follicle at mid-follicular phase becomes the 
dominant follicle. 
 Rising oestrogen and inhibin produced by the dominant follicle inhibit 
pituitary FSH production. 
 Declining FSH levels cause atresia of all but the dominant follicle. 
OVULATION 
 FSH induces LH receptors. 
 LH surge. 
 Proteolytic enzymes within the follicle cause follicular wall breakdown 
and release of the oocyte. 
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THE LUTEAL PHASE 
 The corpus luteum is formed from granulosa and theca cells retained 
after ovulation. 
 Progesterone produced by the corpus luteum is the dominant hormone 
of the luteal phase. 
 In the absence of pregnancy, luteolysis occurs 14 days after ovulation. 
PITUITARY GLAND 
 The process of follicular development, ovulation and the maintenance 
of the corpus luteum has been described in terms of ovarian physiology.  In 
reality however, the ovary, pituitary and hypothalamus act in concert (the 
hypothalamo-pituitary-ovarian asix) to ensure the growth and development of 
(ideally) one ovarian follicle, and to maintain hormonal support of the 
endometrium to allow implantation. 
 The pituitary hormones LH and FSH are, as we have seen, key 
regulators of folliculogenesis.  The output of LH and FSH from the pituitary 
gland is  stimulated by pulses of gonadotrophin-releasing hormone (GnRH) 
produced by the hypothalamus and transported to the pituitary in the portal 
circulation.  The response of the pituitary is not constant but is modulated by 
ovarian hormones, particularly oestrogen and progesterone.  Thus low levels 
of oestrogen have an inhibitory effect on LH (negative feeback) whereas high 
levels of oestrogen actually stimulate pituitary LH production (positive 
feedback).  In the late follicular phase, serum levels of oestrogen are 
sufficiently high so that a positive feedback effect is triggered thus generating 
the periovulatory LH surge.  In contrast, the combine contraceptive pill 
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produces serum levels of oestrogen in the negative feedback range, so that 
measured levels of gonadotrophins are low. 
 The mechanism of action of the positive feedback effect of oestrogen 
involves an increase in GnRH receptor concentrations and an increase in 
GnRH production, whilst the mechanism of the negative feedback effect of 
oestrogen is uncertain. 
 In contrast to the effects of oestrogen, low levels of progesterone have 
a positive feedback effect on pituitary LH and FSH secretion.  Such levels are 
generated immediately prior to ovulation, and contribute to the FSH surge.  
High levels of progesterone such as those seen in the luteal phase  inhibit 
pituitary gonadotrophin production.  Negative feedback  effects of 
progesterone are generated both via decreased GnRH production, and via  
decreased sensitivity to GnRH at the pituitary level. Positive feed-back effects 
of progesterone operate at the pituitary level only and involve increased 
sensitivity to GnRH.  Importantly, progesterone can  only have these effects if 
there has been prior priming by oestrogen. 
 As we have seen, oestrogen and progesterone are not the only 
hormones to have an effect on pituitary gonadotrophin secretion.  The peptide 
hormones inhibin and activin have opposing effects on gonadotrophin 
production: inhibin attenuates pituitary FSH secretion whereas activin  
stimulates it. 
Prolactin 
 Prolactin is secreted  from the alpha cells and is a polypeptide. 
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 Its role in the maintenance of corpus luteum in human  is not well 
documented, but the fact remains that there is high incidence of anovulation in 
women with elevated plasma prolactin level. 
Thyrotrophic Hormone (TSH) 
 TSH (thyroid stimulating hormone) is produced by the beta cells.  It 
acts on the thyroid gland and regulate the production of thyroxine.  It has got 
α and β subunits like those of FSH and LH, with functions of β subunits being 
different.  Abnormal TSH secretion is associated with menstrual and ovulatory 
dysfunction. 
THE HYPOTHALAMUS 
 The hypothalamus, via the pulsatile secretion of GnRH, stimulates 
pituitary LH and FSH secretion.  Production of GnRH not only has a 
permissive effect on gonadotrophin production, but alterations in amplitude 
and frequency of GnRH pulsation throughout the cycle are also responsible 
for some fine tuning of gonadotrophin production. 
 The importance of GnRH secretion is seen in disorders such as anorexia 
nervosa, and the amenorrhoea associated with excessive exercise.  In these 
disorders, GnRH production is suppressed leading to anovulation and amenorrhoea.  
Ovulation can be restored in these women by the administration of GnRH in a 
pulsatile manner (although this should be approached carefully since pregnancy is 
relatively contraindicated in women whose body weight is significantly below average). 
 It is important to remember that GnRH  is produced in a pulsatile 
manner to exert its physiological effect.  Drugs that are GnRH agonists (e.g. 
buserelin and goserilin) are widely used in gynaecology for the treatment of 
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endometriosis and other disorders.  Although these drugs act as GnRH 
agonists, they cause a decrease in pituitary LH and FSH secretion.    The 
reason for this is that these agonists are long acting and the continued 
exposure of the pituitary to moderately high levels of GnRH causes down 
regulation and desensitization of the pituitary.  LH and FSH production is 
therefore markedly decreased.  Ovarian steroidogenesis is suppressed so 
that serum oestrogen and progesterone fall to postmenopausal levels.  Most 
women become amenorrhoeic whilst taking GnRH agonists.  A potential 
disadvantage of the currently available GnRH agonists is that such down-
regulation and desensitization of the pituitary takes up to three weeks to exert 
its effects.  The initial effect of GnRH administration is to stimulate pituitary LH 
and FSH production, leading to increased ovarian steroidogenesis.  When a 
patient commences GnRH therapy, this temporary increase in ovarian 
steroidogenesis leads to a vaginal bleed within the first month of 
administration and it is important to warn the patient of this. 
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HYPERPROLACTINEMIA 
PROLACTIN 
Functions 
 The primary function of prolactin is to enhance breast development in 
pregnancy and to induce lactation after delivery.  In addition, by binding to 
specific receptors in the gonads, lymphoid cells and liver it affects fertility, 
immunity and liver functions. 
HYPERPROLACTINEMIA 
 A condition characterised by elevated serum prolactin levels, is the 
most common endocrine disorder of the hypothalamo – pituitary axis.  It could 
result from a variety of conditions both physiological and pathological.  The 
prevalence varies from less than 1% of the general population, to almost 17 
percent in women with reproductive disorders. 
ETIOLOGY OF HYPERPROLACTINEMIA 
Physiological     Pathological 
REM Sleep     Tumors – Prolactinoma 
Pregnancy     Hypothalamic (pituitary lesions) 
Nipple Stimulation    Idiopathic 
Stress      Polycystic ovarian disease 
Coitus      Hypothyroidism 
      Chest wall injury 
      Renal Failure 
      Liver Failure 
      Drugs – dopamine analogs 
      Phenothiazines 
      Estrogen 
      Opiates 
      Cimetidine 
      Methyldopa 
      Reserpine. 
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EFFECT ON FEMALE REPRODUCTIVE FUNCTION 
 Prolactin has a significant effect on the female reproductive function by 
acting on the hypothalamo-pituitary ovarian axis.  In addition, it has a direct 
action on the ovaries,  which is supposed to be responsible for the menstrual 
irregularities associated with hyperprolactinemia ; probably regulating ovarian 
steroidogenesis by its actions on the aromatase enzyme.  It is interesting to 
note that the action of prolactin on the ovaries varies in the different phases of 
the menstrual cycle. 
 In the follicular phase, elevated prolactin level can disrupt normal 
follicular development, cause atresia of the dominant follicle and inhibit 
ovulation.  On the other hand, the role of prolactin in the luteal phase is not 
very clear, as it is supposed to both stimulate (by inducing LH receptor 
formation) and inhibit corpus luteal functions (by inhibiting corpus luteal 
steroidogenesis).  Animal experiment have found that elevated prolactin level 
can induce the development of adenomyosis – a condition characterized by 
the implantation or extension of the endometrial glands into the myometrium, 
apart from ovulatory dysfunction that could cause the infertility associated with 
hyperprolactinemia. 
Effect of Hyperprolactinemia on female reproductive function 
1. Disrupts normal follicular development. 
2. Atresia of the dominant follicle. 
3. Inhibits aromatase enzyme. 
4. Inhibits progesterone synthesis by the corpus luteum. 
5. Premature destruction of the corpus luteum. 
6. Induces uterine adenomyosis. 
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DIAGNOSIS 
 As prolactin is a dynamic hormone that responds readily to a variety of 
stimuli, caution must be exercised during diagnosis. 
 Women typically present with a history of amenorrhea, oligomenorrhea 
or infertility.  Occasionally galactorrhea may be the only presenting symptoms.  
Both sexes may present with visual field defects and headaches if associated 
with a pituitary tumour. 
Common Presenting symptoms in prolactin related disorders. 
1. Amenorrhoea 
2. Oligomenorrhoea 
3. Galactorrhoea 
4. Unexplained Infertility 
5. Headache 
6. Visual field defects 
7. Symptoms of hypothyroidism 
8. Drug intake 
9. Decreased libido 
Adjuvant investigation in a case of hyperprolactinemia 
1. Serum TSH 
2. BUN - Blood Urea Nitrogen 
3. Serum Creatinine 
4. Liver function tests 
5. Visual field testing 
6. CT - Brain 
7. MRI - Brain 
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THYROID DISORDERS IN INFERTILITY 
Thyroid disorders both hypo and hyperthyroidism are known  to have  a 
profound effect on pregnancy and reproduction. 
HYPERTHYROIDISM 
 The  effect of severe hyperthyroidism on the fertility potential of an 
individual is well documented, but the effects of the mild and moderate forms 
of this disorders are not very clear. 
ETIOLOGY OF HYPERTHYROIDISM 
1. Grave's disease. 
2. Solitary toxic nodule. 
3. Toxic multinodular goitre. 
4. Acute thyroiditis- viral 
a. Autoimmune 
b. Post-radiotherapy 
5. Thyrotoxicosis.  
6. Exogenous iodine administration. 
7. Metastatic differentiated thyroid carcinoma. 
8. TSH secreting tumours. 
9. HCG secreting tumours. 
10. Hyperfunctioning ovarian teratomas.  
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CLINICAL FEATURES 
Symptoms 
¾ Hyperactivity, 
¾ irritability, dysphoria 
¾ Heat intolerance and sweating 
¾ Palpitations 
¾ Fatigue and weakness 
¾ Weight loss  with increased appetite 
¾ Diarrhoea 
¾ Polyuria 
¾ Oligomenorrhoea, loss of libido. 
Signs 
 Tachycardia: atrial fibrillation in the elderly 
¾ Tremor 
¾ Goiter 
¾ Warm, Moist skin 
¾ Muscle weakness, proximal myopathy 
¾ Lid refraction or lag 
¾ Gynaecomastia. 
 51
HYPERTHYROIDISM AND FEMALE FERTILITY 
 Elevated  thyroxine concentrations lead to increased levels of the sex 
hormons binding globulin.  This, in  turn, accounts for the raised 
concentrations of Estradiol and testosterone in the blood.  Apart from this , the 
fallicular phase baseline serum FSH and LH concentrations are also 
increased with an attenuated mid-cycle LH surge.  Consequently oligovulatory 
or anovulatory cycles  with a wide range of menstrual disorders  (ranging from 
amenorrhoea to menometrorrhagia) may be seen. 
DIAGNOSIS 
 The diagnosis of hyperthyroidism is based upon clinical findings and 
serological assays. 
 Assessment of  the clinical manifestations would give a reasonable 
indication to the presence of the disorders, which could then be  confirmed by 
serum hormonal assay. 
 The best screening tool, however, is the serum TSH assay.  This is 
based on the fact that as the level of the serum T3 and T4 rise, the 
concentration of TSH will  fall exponentially giving an accurate estimation of 
the severity of the condition. 
 Once the diagnosis is established  further tests to identify  a possible 
cause may be carried out- ultrasound, radioactive iodine uptake, anti thyroid 
antibody titers etc. 
 Serum TSH 
 Serum T4 
 Serum T3 
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 Radioactive Iodine uptake  
 Ultrasound 
 Antithyroid antibodies. 
HYPOTHYROIDISM 
 Hypothyroidism is characterized by a spectrum of clinical 
manifestations that are directly or indirectly related to the deficiency of the 
thyroid hormones. 
 Moderate and severe degrees of hypothyroidism have a detrimental 
effect on the reproductive potential of both men and women, but the same 
cannot be said of the mild and sub-clinical forms. 
 Primary hypothyroidism is due to thyroid gland failure, while secondary 
hypothyroidism occurs due to disorders of the hypothalamo - pituitary axis, 
which results in the inadequate production of bio-active TSH. 
ETIOLOGICAL FACTORS OF HYPOTHYROIDISM 
Primary 
1. Congenital - Agenesis  
   Ectopic thyroid remnants. 
2. Defect in synthesis -  
   Iodine deficiency 
   Dyshormogenesis 
   Antithyroid drugs 
3. Autoimmune 
   Hashimoto's thyroiditis. 
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4. Atrophic. 
5. Infective. 
6. Post - surgery. 
7. Post - radiotherapy. 
8. Peripheral resistance to thyroid hormones. 
Secondary 
1. Hypopituitarism. 
2. Isolated TSH deficiency.  
CLINICAL FEATURES 
Symptoms 
¾ Tiredness, weakness 
¾ Dry skin 
¾ Feeling cold 
¾ Hair loss 
¾ Difficulty concentrating and poor memory 
¾ Constipation 
¾ Weight gain with poor appetite 
¾ Dyspnea 
¾ Hoarse voice 
¾ Menorrhagia (later oligomenorrhoea or amenorrhoea) 
¾ Paresthesia 
¾ Impaired hearing 
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Signs 
¾ Dry coarse skin; cool peripheral extremities 
¾ Puffy face, hands and feet (myxedema) 
¾ Diffuse aloepecia 
¾ Bradycardia 
¾ Peripheral oedema 
¾ Delayed tendor reflex relaxation 
¾ Carpal tunnel syndrome 
¾ Serous cavity effusions 
HYPOTHYROIDISM AND FEMALE FERTILITY 
 The effect of hypothyroidism on the reproductive potential has been 
well documented in women probably due to the fact this disorder is more often 
seen in females. 
 Menstrual irregularities, spontaneous first trimester miscarriages, 
permature deliveries, unexplained stillbirths and infertility are some of the 
manifestations. 
 Almost 70 percent of infertility in hypothyroid females is due to 
anovulation. 
 Hypothyroidism is also common in women with unexplained infertility, 
and not often seen in women with tubal factor. 
 Menstrual irregularities are seen in approximately 23 to 25 percent. 
Oligomenorrhoea is probably the most common clinical manifestation. 
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 Menorrhagia, sometimes  seen in these women is due to a combination 
of anoulation, poor uterine muscle tone and platelet dysfunction. 
DIAGNOSIS 
 Confirmation of the diagnosis is by serological assay, which would 
demonstrate a deficiency of the thyroid hormones. 
Thyroid function Test 
Test Use Misleading 
Total T4 Hypothyroidism Pregnancy 
Free T4 Thyrotoxicosis 
Hypothalmo - pituitary disease 
Estrogen therapy 
NSAID therapy 
Total T3 Thyrotoxicosis screening  
TSH Neonatal hypothyroidism 
Thyrotoxicosis 
Hypothalamo pituitary disease 
 
 
 Once the  diagnosis is established, the presence of autoimmune 
disorders must be looked for. Assay of antimicrosomal antibodies and 
antithyroglobulin antibodies are useful indicators of the risk of progression. 
 Screening for hypothyroidism is best done using a sensitive TSH 
assay. However, this may not be very accurate in conditions that do not 
produce enough bioactive TSH as seen in recent onset hypothyroidism and in 
hypothalamo-pituitary disorders. In these cases it would be better to assay 
free T4 along with the TSH. 
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POLYCYSTIC OVARIAN SYNDROME  (PCOS) 
 In  1935, Irving F. Stein and Michael L. Leventhal first described a 
symptom complex associated with infertility.  They described 7 patients, 4 of 
whom were  obese, with amenorrhoea, hirsutism and enlarged polycystic 
ovaries. Based on their observation that, several amenorrhoeic patients 
menstruated after ovarian biopsy, they subjected the 7 patients to bilateral 
wedge resection, wherein, they removed half to three-fourth of each ovary.  
They observed that all 7 women resumed regular menses and 2 of them even 
conceived. 
 The  National Institute of Health Conference (1990) gave a working 
definition whereby it is enough if a patient has chronic ovulatory dysfunction 
and any evidence of hyperandrogenism excluding other causes such as adult 
onset congenital adrenal hyperplasia (CAH) Cushing’s syndrome, androgen 
secreting neoplasms. 
 The  incidence varies between 0.5-4 per cent, more common amongst 
infertile women.  It is prevalent in young reproductive period. 
PATHOLOGY 
 Typically,  the ovaries are enlarged two to five times the normal size.  
Stroma is increased.  The capsule is thickened and pearly white in colour.  On 
bisection, multiple follicular cysts measuring about 8-10mm in diameter are 
crowded around the cortex. 
 Histologically, there is thickening of tunica albuginea.  The cysts are 
follicles at varying stages of maturation and atresia.  There is theca cell 
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hypertrophy (stromal hyperthecosis).  Patient  may present with features of 
diabetes mellitus (insulin resistance). 
CLINICAL FEATURES 
 The patient  complains of increasing obesity, menstrual abnormalities 
in the form of oligomenorrhoea, amenorrhoea or DUB (Dysfunctional uterine 
bleeding) and infertility.   
 Amenorrhoea  was the presenting complaint for all the patients in the 
series reported by stein and leventhal, however, Gold heizer in his class 
review of 187 reports described 1079 cases, he identified amenorrhoea in an 
average of 47% of patients only, while 16% had regular menses. Conway and 
co-workers found 20-25% of patients  with ultrasound findings of polycystic 
ovarian syndrome, to have regular period.  Grossly abnormal menstrual 
cycles usually signal ovulatory dysfunction.  There may  be hirsutism.  Virilism 
is rare.  The patient may not always be obese. 
 Acanthosis  nigricans is characterized by specific skin changes due to 
insulin resistance.  The skin is thickened and pigmented.  Commonly affected 
sites are nape of the neck, inner thighs, and axilla. 
 HAIR-AN  syndrome in patients with  PCOS is characterized by 
hyperandrogenism, insulin resistance and acanthosis nigricans. 
 Internal  examination reveals bilateral enlarged cystic ovaries which 
however, may not be revealed  due to obesity. 
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INVESTIGATIONS 
Sonography 
 Transvaginal sonography is specially useful in obese patient.  Ovaries 
are enlarged in volume.  Increased number of peripherally arranged cysts are 
seen. 
Serum values 
• LH level is elevated and  / or the ratio LH: FSH is > 3:1. 
• Reversible oestradiol: oestrone ratio – The oestrone level is 
markedly elevated. 
• SHBG level is reduced. 
• Androstenedione is elevated. 
• Serum testosterone and DHEA –S may be marginally elevated. 
• Raised serum insulin level (insulin resistance) / or the ratio of 
fasting glucose : fasting insulin is <4.5 
Laparoscopy  
 Bilateral polycystic ovaries are characteristic of PCOS. 
PATHOPHYSIOLOGY 
 Exact pathophysiology of PCOS is not clearly understood.  It may be 
discussed  under the following heads . 
(a) Hypothalamic – Pituitary compartment abnormality. 
(b) Androgen excess  
(c) Anovulation. 
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(d) Obesity and insulin resistance. 
(e) Long-term consequences 
HYPOTHALAMIC – PITUITARY COMPARTMENT IN PCOS 
 
¾ Increased pulse frequency of GnRH leads to increased pulse 
frequency of L.H. (Leptin, a peptide, secreted by fat cells and by the 
ovarian follicle, in presence of hyperinsulinaemia may be responsible 
for this). 
¾ GnRH is preferential  to LH rather than FSH. 
¾ Increased pulse frequency and amplitude of LH results in tonically 
elevated level of LH. 
¾ FSH level  is not increased.  This is mainly due to the negative feed 
back effect of chronically elevated oestrogen and the follicular inhibin. 
¾ Increased free oestradiol due to reduced sex hormone binding globulin 
(SHBG) bears positive feedback relationship to LH. 
¾ The LH: FSH ratio is increased. 
ANDROGEN EXCESS 
 Abnormal  regulation of  the androgen forming enzyme (P450 C17) is 
thought  to be the main cause for excess production of androgens from the 
ovaries and adrenals.  The principal sources of androgens are (A) Ovary (B) 
Adrenal (C)  Systemic metabolic alteration. 
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A. Ovary  produces excess androgens due to: 
  (i) Stimulation of theca cells by high LH 
 (ii) P450 C17 enzyme hyperfunction 
 (iii) Defective aromatisation  of androgens to oestrogen 
 (iv) Stimulation of theca cells by IGF-1 (insulin growth factor-1). 
B. Adrenals are stimulated to produce excess androgens by: 
 (i) Stress 
 (ii) P450 C17 enzyme hyperfunction 
 (iii) Associated high prolactin level (20%). 
C. Systemic metabolic alteration 
(i) Hyperinsulinaemia causes :  
 (a) Stimulation of theca cells to produce more androgens. 
 (b) Insulin results in more free IGF-1.  By autocrine action,  
  IGF-1 stimulates theca cells to produce more androgens.  
 (c) Insulin inhibits hepatic synthesis of SHBG, resulting  in  
  more free level of androgens. 
 Features  Suggestive of insulin resistance are: BMI >27 kg / M2, 
Acanthosis nigricans  and waist to hip ratio > 0.85. 
(ii) Hyperprolactinaemia 
 In about  20 per cent cases, there may be mild elevation of prolactin 
level due to increased pulsitivity of GnRH or due to dopamine deficiency or to 
both.  The prolactin further stimulates adrenal androgen production. 
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ANOVULATION 
 Because of low FSH level, follicular growth is arrested at different 
phases of maturation (5-10 mm diameter).  The net effect is diminished 
oestradiol and increased inhibin production.  Due to elevated LH, there is 
hypertorophy of theca cells and more androgens are produced either from 
theca cells or stroma. 
 There is defective FSH induced aromatisation of androgens to 
oestrogens. 
 Follicular  microenvironment is therefore more androgenic rather than 
oestrogenic. 
 Unless there is oestrogenic follicular micro-environment, follicular 
growth, maturation  and ovulation cannot occur.  There is huge number if 
atretic follicles that contribute to increased ovarian stroma (hyperthecosis).  
LH level is tonically elevated without any surge.  LH surge is essential for 
ovulation to occur. 
OBESITY AND INSULIN RESISTANCE 
 Obesity has been classically regarded as an important feature but its 
presence it extremely visible being found in 35-60% of polycystic ovarian 
syndrome.   It has no diagnostic value but the greater the body mass index, 
the higher the testosterone levels and hirsutism. They have a characteristic 
distribution of body fat known as android obesity. The fat is metabolically 
active and less sensitive to insulin. It is associated with hyperinsulinemia  
impaired glucose tolerance, decrease in SHBG and increase in the level of 
testosterone. A waist hip ratio greater than 0.85 indicates android fat 
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distribution.  Hyperinsulinemia and hyperandrogenism  however, are not 
confined to obese polycystic ovarian syndrome.  However, insulin levels are 
higher, luteinizing  hormone, SHBG and IGFBP-1 levels are lower in obese, 
compared to non-obese individuals.  Obesity, defined as BMI greater than 27 
is found in 30-35% of women with polycystic ovarian syndrome.  Hirsutism is 
found  in 70-73% of obese polycystic ovarian syndrome compared to  56-58% 
of normal weight polycystic ovarian syndrome and infertility is 40% more in 
polycystic ovarian syndrome with BMI greater than 30 .  Also  menstrual 
cycles are more irregular. 
LONG  TERM CONSEQUENCES IN A PATIENT SUFFERING FROM PCOS 
INCLUDES 
 The excess androgens (mainly androstenedione) either from the 
ovaries or adrenals are peripherally aromatised to oestrone (E1).  There is 
concomitant diminished SHBG.  Cumulative excess unbound E2 and oestrone 
results in a tonic hyperoestrogenic state.  There is endometrial hyperplasia. 
 Risk of developing diabetes  mellitus due to insulin resistance.. 
 Risk of developing endometrial carcinoma due to persistently elevated 
level of oestrogens.  Oestrogen effects are not opposed by 
progesterone because of chronic anovulatory state. 
 Risk of hypertension and cardiovascular disease due to abnormal lipid 
profile. 
 
 
 63
DIAGNOSIS OF OVULATION 
 The various methods used in practice to detect ovulation are grouped 
as follows: 
 Diagnosis of ovulation 
Indirect 
   Menstrual history 
   Evaluation of peripheral or endorgan changes 
• BBT (Basal Body Temperature) 
• Cervical mucus study 
• Vaginal cytology 
• Horomone estimation 
- Serum progesterone 
- Serum LH 
- Serum oestradiol 
• Endometrial biopsy 
 Sonography 
Direct  
    Laparoscopy 
Conclusive 
    Pregnancy 
 
INDIRECT 
 The  indirect or presumptive evidences of ovulation are commonly used 
in clinical practice.  These are inferred from: 
• Menstrual history. 
• Evaluation of peripheral or end-organ changes due to oestrogen and 
progesterone. 
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• Direct assays of gonadotrophins or steroid hormones preceeding, 
coinciding or succeeding the ovulatory process. 
MENSTRUAL HISTORY  
 The  following features in relation to menstruation are strong evidences 
of ovulation. 
• Regular normal menstrual loss between the age of 20-35. 
• Midmenstrual bleeding (spotting) or pain or excessive mucoid vaginal 
discharge (Mittelschmerz syndrome) 
• Features suggestive of premenstrual syndrome or primary 
dysmenorrhoea. 
EVALUATION  OF PERIPHERAL OR ENDORGAN CHANGES 
Basal body temperature (BBT) 
 Observation – There is “biphasic pattern”  of temperature  variation in 
ovulatory cycle.  If pregnancy occurs, the rise of temperature  sustains along 
with absence of the period.  In anovulatory cycle, there is no rise of 
temperature throughout the cycle. 
 Principle – The rise of temperature is secondary to progesterone 
output.  The primary reason for the rise is the increase in the production and 
secretion of norpinephrine which is thermogenic neural hormone. 
 Procedures – The patient is instructed to take her oral temperature 
daily on waking in the morning before rising out of the bed.  The temperature 
is recorded on a special chart.  Days when intercourse takes place should 
also be noted on the chart for better evaluation of coital frequency. 
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 Interpretation – The body temperature  maintaining throughout the 
first half of the cycle is raised to 0.5 to   10F (0.2-0.50C) following ovulation.  
The rise sustains throughout the second half of the cycle and falls about 2 
days prior to the next period  - called “biphasic pattern”.  There may be a drop 
in the temperature to about 0.50F  before the rise and almost coincides with 
either LH surge or ovulation.  The demonstrable rise actually occurs about 2 
days after the LH peak and with a peripheral level of progesterone to greater 
than 4 ng / ml. 
 Clinical Importance – Maintenance of BBT charge during 
investigation is of help in determining ovulation and timing of post coital test, 
endometrial biopsy, cervical mucus or  vaginal cytology study for ovulation.  It 
also helps the couple to determine the most fertile period, if the cycle is 
irregular. 
Limitations of BBT 
• BBT indicates ovulation retrospectively. 
• It cannot predict ovulation precisely with time. 
• Rarely ovulation has been observed though BBT is monophasic.  
 It should not be continued for more than 3-4 months for investigation 
purpose.  However, it has to be maintained for longer periods during 
management of ovulation induction. 
Cervical mucus study 
 Alteration of the  physico-chemical properties of the cervical mucus 
occurs due to the effect of oestrogen and progesterone. 
 66
 Disappearance of fern pattern  beyond 22nd day of the cycle which was 
present in the midcycle is suggestive of ovulation.  Persistence of fern pattern 
even beyond 22nd day suggests anovulation.  Progesterone causes 
dissolution of the sodium chloride crystals.  Following ovulation, there is loss 
of stretchability (spinbarkeit) which was present in the midcycle. 
Vaginal cytology  
 Maturation index shifts to the left from the midcycle to the mid second 
half of cycle due to the effect of progesterone.  However, a single smear on 
day 25 or 26 of the cycle reveals features of progesterone effect,  if ovulation 
occurs. 
Hormone estimation 
 Serum  progesterone – Estimation of serum progesterone is done on 
day 8 and 21 of a cycle.  An increase in value from less than 1 ng / ml to 
greater than 6 ng / ml suggests ovulation. 
 Serum  LH – Daily estimation of serum LH at midcycle can detect the 
LH surge.  Ovulation occurs about 34-36 hours after beginning of the LH 
surge.  It coincides about 10-12 hours after the LH peak. 
 Serum  oestradiol - attains the peak rise approximately 24 hours prior 
to LH surge and about 24-36  hours prior to LH surge and about  24-36 hours 
prior to ovulations. 
 The serum LH  and oestradiol estimation is used for in vitro fertilization. 
 
 
 67
Endometrial biopsy  
 Endometrial  tissues to detect ovulation (endometrial sampling) can 
easily be obtained as an out-patient procedure using instruments such as 
Sharman curette or Pipelle endometrial sampler.  Dilatation and curettage is 
however reserved in cases where bulk endometrial study is required as in 
endometrial tuberculosis. 
 Biopsy is to be done on 21-23rd day of the cycle.  Barrier contraceptive 
should be prescribed during the cycle to prevent accidental conception.  
However, if the cycle is irregular, it is done within 24 hours of the period. 
 Findings  - Evidences of secretory activity of the endometrials glands in 
the second half of the cycle give not only the diagnosis of ovulation but can 
predict the functional integrity of the corpus luteum. 
 Subnuclear  vacuolation is the earliest  evidence appearing 36-48 
hours following ovulation. 
 Cause -  The secretory changes are due to the action of progesterone 
on the oestrogen primed endometrium. 
SONOGRAPHY 
 Serial  sonography during  midcyle can precisely measure the Graafian 
follicle just prior to ovulation (18-20 mm).  It is particularly helpful for 
confirmation of ovulation following ovulation induction, artificial insemination 
and  invitro fertilization.  The features of recent ovulation are collapsed follicle 
and fluid in the pouch of Douglas. 
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DIRECT 
Laparoscopy  
 Laparoscopic visualization of recent corpus luteum or detection of the 
ovum from the aspirated peritoneal fluid from the pouch of Douglas is the only 
direct evidence of ovulation. 
CONCLUSIVE 
 Pregnancy is the surest evidence of ovulation. 
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MATERIALS AND METHODS 
POPULATION AND SAMPLE 
 The population consists of Penn Maladu (Polycystic ovarian disease, 
Hypothyroidism) patients satisfying the inclusion and exclusion criteria 
mentioned below. 
 The sample consists of Penn Maladu patients attending the OPD of 
Ayothidoss Pandithar Hospital of National Institute of Siddha, Chennai - 47. 
SAMPLE SIZE 
 The trial size will be 20 patients 
INCLUSION CRITERIA 
a. Age 20 to 40 years 
b. Normal report of semen analysis of male partner 
c. Willing to produce sonography before the start of the trial 
d. Willing to give blood specimen for investigation when required 
EXCLUSION CRITERIA 
 1. Congenital Defects 
2. Endometriosis 
3. Tuberculosis 
4. Sexually transmitted disease 
5. Genital Malignancy 
6. Tubal factors 
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WITHDRAWAL CRITERIA 
1. Development of severe adverse drug reactions 
2. Occurrence of any other serious illness 
TRIAL DRUG, DOSAGE, DURATION 
 1. Maladu Neenga Thailam : 3g o.d. at morning for the first  
       3 days of a menstrual cycle. 
2. Saaravalli Mathirai  : 2g b.d.  from 4th day of  
      menstrual cycle to 30th day  
      Trial treatment period is 90  
      days or 3 cycles. 
TESTS AND ASSESSMENTS 
(a) CLINICAL ASSESSMENT 
Oligomenorrhoea, Amenorrhoea, Regular Periods, Hypomenorrhoea, 
Pain during menstruation. 
(b) INVESTIGATIONS 
1. Blood Test 
TC, DC, ESR, Hb, Blood Sugar, Serum Creatinine, Serum 
Cholesterol, Serum Progesterone, FSH, LH, T3, T4, TSH. 
2. Sonography 
3. Urine Analysis 
Albumin, Sugar, Deposits, HCG. 
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(c) TEST IN SIDDHA ASPECTS 
 Envagai Theruvugal 
Naadi, Sparism, Naa, Niram, Mozhi, Vizhi, Malam, Moothiram 
 Neerkuri 
Nirma, Edai, Manam, Nurai, Enjal 
 Neikuri 
CONDUCT 
 Penn Maladu patients satisfying the inclusion and exclusion criteria will 
be admitted to this trial.  Informed consent will be obtained from the patients. 
 They will be instructed to come for next visit after 7 days and asked to 
bring back the unconsumed drug during their next visit and return the same. 
FORM 
 (A) Form – I : Selection Proforma  - It is used before admission  
           to the Trial 
 (B) Form-II  : Assessment Proforma – It is used during clinic  
        visits once in 7 days. 
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OBSERVATION AND RESULTS 
Table - 1 
Age Distribution 
Age Cases 
No Percentage (%) 
20 – 25 3 15% 
26 – 30 7 35% 
31 – 36 7 35% 
36 – 40 3 15% 
Total 20 100% 
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Table - 2 
Occupation History 
Working in Night 
Shifts 
Cases 
No Percentage (%) 
Yes 1 5% 
No 19 95% 
Total 20 100% 
 
Table - 3 
Food Habits 
Food Habits Cases 
No Percentage (%) 
Veg 2 10% 
Non-Veg 18 90% 
Total 20 100% 
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Table - 4 
Years of Infertility 
Duration (Yrs) 
Cases 
No Percentage (%) 
0 - 3 6 30% 
3 – 6 9 45% 
6 – 9 2 10% 
10 + 3 15% 
Total 20 100% 
 
Table  - 5 
Thinai 
Duration (Yrs) 
Cases 
No Percentage (%) 
Kurunji 1 5% 
Mullai 0 0% 
Marutham 0 0% 
Neithal 19 95% 
Palai 0 0% 
Total 20 100% 
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Table - 6 
Distribution of Anovulatory Infertility 
Anovulation  No of Cases Percentage (%) 
PCOD 15 75% 
PCOD + Hypothyroidism 3 15% 
Hypothyroidism 2 10% 
Total 20 100% 
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Table - 7 
Distribution of Menstrual Pattern 
Menstrual Pattern 
PCOD PCOD + 
Hypothyroidism 
Hypothyroidism 
No of 
Cases 
Percentage 
(%) 
No of 
Cases 
Percentage 
(%) 
No of 
Cases 
Percentage 
(%) 
Oligomenorrhoea 9 45% 1 5% 0 0% 
Amenorrhoea 3 15% 2 10% 0 0% 
Regular Periods 3 15% 0 0% 2 10% 
Hypomenorrhoea 6 30% 1 5% 2 10% 
 
Table - 8 
Udal Thathukkal 
Udal Thathukkal No. of Cases Percentage (%) 
Saarum 20 100% 
Senneer 7 35% 
Oon 1 5% 
Kozhuppu 2 10% 
Enbu 0 0% 
Moolai 0 0% 
Suronitham 20 100% 
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Table - 9 
Neerkuri 
Neerkuri No of Cases Percentage (%) 
Pale Yellow 10 50% 
Yellow 5 25% 
Dark Yellow 2 10% 
Straw 1 5% 
Total 20 100% 
 
Table - 10 
Neikuri 
Neikuri No of Cases Percentage (%) 
Slowly Spread 15 75% 
Fastly Spread 2 10% 
Muthu 3 15% 
Total 20 100% 
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Table - 11 
Envagai Thervu 
Envagai Thervu No of Cases Percentage (%) 
Naa 
  Dryness 
 
2 
 
10% 
Niram 
  Vatham 
  Pitham 
  Kapham 
 
9 
6 
5 
 
45% 
30% 
25% 
Mozhi 0 0% 
Vizhi 0 0% 
Malam 5 25% 
Moothiram 0 0% 
Sparisam 
  Veppam 
  Thatpam 
 
2 
18 
 
10% 
90% 
Naadi  
  Vatha Pitham 
  Pithavatham 
  Vathakapham 
 
10 
8 
2 
 
50% 
40% 
10% 
 
Table - 12  
Result 
Anovulatory Infertility PCOD + 
Hypothyroidism 
Hypothyroidism 
Ovulation / Fertility 13 2 
Failure 5 - 
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DISCUSSION 
Age Distribution 
 Out of 20 patients, most of  were between 25 – 35 yrs of age.  Due to 
late marriages now-a-days, the distribution of age among infertility patients is 
increased to 25-35 yrs. 
 Though ovulation is same in all age groups, the decline in fertility 
begins in the early thirties and accelerates in late thirties and early forties. 
Occupational History 
 Out of 20 patients, one is working in night shifts.  Due to alteration in 
the circadian rhythm and stress,  the menstrual  pattern is also affected.  This 
may be the one of the cause for infertility. 
Food Habits 
 Out of 20 patients, 18 were non-vegetarians.  In the fast pace of 
modern life, dietary habits lead to obesity and a decline  in fertility rate. 
Years of Infertility 
 Out of 20 patients, 15 patients were below six years of duration.  They 
have good improvement. 
Thinai 
 Most of the patients came from Neithal Thinai.  Commonly Vali is 
deranged in its state in this thinai.  Abana Vayu is affected in female infertility 
patients. 
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Clinical Features 
 Patients enrolled had varying menstrual patterns from regular periods 
through oligomenorrhoea to amenorrhoea.  
Oligomenorrhoea 
 Out of 20 patients, 10 patients has Oligomenorrhoea in whom 
menstrual bleeding occuring more than 35 days apart and which remains 
constant at that frequency.  All the patients were improved and had regular 
periods. 
Amenorrhoea 
 Out of 20 patients, 5 patients had Amenorrhoea.  All the 5 patients 
menstruate after the treatment.  But ovulation / fertility is not achieved. 
Regular Periods 
 Out of 20 patients, 5 patients had regular periods, but biochemical 
markers of infertility are positive.  Of them, 3 becomes pregnant and 2 has 
ovulation. 
Hypomenorrhoea 
 Out of 20 patients,  9 patients had hypomenorrhoea.  All are relieved 
from the symptoms after treatment. 
Vali 
 Amenorrhoea, Oligomenorrhoea, Hypomenorrhoea are due to 
deranged Abana Vayu.  15 patients affected by Abana Vayu. 
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Azhal 
 Sathaga Pitham (life energy) was affected in most of the infertility 
patients. 
Udal Thathukkal 
 Suronitham affected in all patients. Saarum affected in 20 patients.  
Senneer affected in 7 patients.   Derangement of  Suronitham, saarum, 
senneer or any one of  this lead to development of infertility.  Sometimes oon 
& kozhuppu may be affected. 
Envagai Thervu 
 Niram-9 patients came with Vatha niram, 6 patients came with pitha 
niram and  five with kapha niram. 
 Sparisam- Sparisam was veppam in  2 patients , thatpam in 18 
patients. 
 Malam was affected in 5 patients due to hypothyroidism . 
 Nadi – Vatha pitham & pithavatham was the commonest nadi in 
majority of cases. 
Neerkuri 
 The colour of the urine was pale yellow in 10 patients, yellow in 5 
patients, dark yellow in 2 patients.  The yellow colouration is due to 
pithathontham. 
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Neikuri 
 Most of the patients it was slowly spread (i.e.) curable condition.  
Result 
 Out of 20 Anovulatory patients 15 ovulate and 8 of them even 
conceived.  Failure of ovulation is in 5 patients. 
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SUMMARY 
 
 The aim of the study is to evaluate the efficacy of the Siddha drugs 
‘Maladu Neenga Thailam and Saaravalli Mathirai’ for the treatment of Penn 
Maladu.  The drugs are prepared as per the literature. 20 patients are 
selected for the trial, based on inclusion and exclusion criteria. 
 Before  treatment,  consent is obtained from the patients.  With the help 
of routine blood and urine examination biochemical parameters, clinical 
markers and ultrasound, diagnosis is made.  At least two markers should be 
positive.  
 They are given trial drugs for 7 days and is instructed to come for next 
clinical visit after 7 days.  Also they are asked to bring back the unconsumed 
drug during their next visit and return the same.  The assessment form is 
noted in every clinical visit. 
 At the end of treatment the clinical symptoms are reduced in majority of 
patients and ovulation occured in 75% patients.  Of them 40% patients even  
conceived. There is failure of ovulation in 25% patients.  After treatment no 
adverse-effect is noted. 
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CONCLUSION 
 
 Clinical trial revealed that the trial drugs "Maladu Neenga Thailam and 
Saaravalli Mathirai" produce ovulation in 75% of cases and failure of ovulation 
in 25% of cases. 
 There is no adverse effects observed during the course of treatment.           
It is concluded that these Drugs are effective in the treatment of Penn Maladu. 
 Because of the encouraging results clinically, the study may be 
undertaken with the same drugs for a prolonged period of time in more 
number of cases and it may throw new lights for the treatment of Penn 
Maladu. 
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ANNEXURE-I 
PREPARATION OF TRIAL MEDICINE 
TRIAL DRUG 1 
 
MALADU NEENGA THAILAM 
Ingredients 
 Raw drugs   - Each 250 gm 
 1.  Seeds of Kumatti - Citrullus colocynths 
 2.  Seeds of Nervalam - Croton tiglium 
 3.  Garlic   - Allium Sativum 
 4.  Seeds of Aamanakku - Ricinus communis 
Method of Preparation 
 All the above raw drugs are put into kuzhithaila Karuvi and burnt with 
50 dried cow dung cakes.  Then the oil obtained from the raw drugs is 
collected. 
Dose    : 3 grams as single dose on morning in empty  
     stomach. It produces purgation. 
Duration   : On the first 3 days of menstruation. 
Literature evidence : Agasthiyar Kanagamani 100 Page No.34. 
Fkl;b tpij 
Botanical name  : Citrullus Colocynthis 
 Rit - ifg;G>  jd;ik - ntg;gk;> gphpT - fhh;g;G 
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Fzk; 
 fpilnaq;Nf Nrhk;gnyq;Nf NfLwr;nra; thjf; 
 filnaq;Nf ahw;Wf;  fypq;f - kiljpwf;fpd; 
 mz;il ailr;rnyq;Nf ahapioahh; #jfj;jpd; 
 cz;il  Ailr;rnyq;Nf NahJ.  (Nj.F) 
Chemical Constituents 
 Colocynthin, Colocynthein, Colocynthetin 
Neh;thsk; 
Botanical name  - Croton tiglium. Linn 
Rit - ntFl;lYld; $ba  ifg;G> jd;ik-ntg;gk;> gphpT-fhh;g;G. 
Fzk; 
 Xjp Yjtj; JWkyk;gd; Ndha; tpyFk; 
 Ngjp kUe;jpw; nghpjhFk; - thjkWq; 
 $h;this nahj;jtpopf; nfhk;gidNa! gz;bjh; nrhy; 
 Neh;thsf; nfhl;ljid eP.   (m.F) 
Chemical  Constituents 
 Tiglinic acid, Crotonic or quartenylic acid, Crotonoleic acid 
nts;Ss;sp 
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Botanical Name : Allium Sativum, Linn 
Rit - fhh;g;G> jd;ik-ntg;gk;> gphpT-fhh;g;G. 
Fzk; 
 rd;dpnahU thje; jiyNehT jhs;typ 
 kd;dptU ePh;f;Nfhit td;rPjk; - md;dNk! 
 cs;Ss;sp fz;gha; cis%y NuhfKk; Nghk; 
 nts;Ss;sp jd;dhy; ntUz;L.  (m.F) 
Chemical Constituents 
 Volatile essential oil contains allyl, propyl, disulphide and other organic 
sulphides or sulphur compounds. 
Mkzf;F tpij 
Botanical Name : Ricinus inermis 
Rit - ifg;G> jd;ik-ntg;gk;> gphpT-fhh;g;G 
Fzk; 
  thjj; njhlf;if tunthl;lh kw;gbf;Ff; 
  fhjj;Jf;; fg;ghw; fbANk - #jj;ijg; 
  Nguz;lg; ge;jpf;Fk; Ngjpf;F Neha;f;fhl;il 
  Nauz;l nkd;gjpdpNa.    (Nj.ntz;gh) 
Chemical Constituents 
 Ricinoleate of glycerol, and tri-ricinolein 
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TRIAL DRUG - 2 
SAARAVALLI MATHIRAI 
Ingredients 
Raw Drugs 
Omum – Carum Coptium     - 120gms 
Chithramoola verpattai – Plumbago zeylanica  - 110gms 
Kadukkai Thol – Terminalia chebula   - 100gms  
Kostum – Costus Speciosus    - 90gms 
Thippili – Piper longum     - 80gms 
Milagu - Piper nigrum     - 70gms 
Chukku – Zingiber officinale    - 60gms 
Sevvrium – Root of Piper nigrum    - 50gms 
Kothamalli – Coriandrum Sativum    - 40gms 
Vaividangam – Embelia ribes    - 30gms 
Seeragam – Cuminum cyminum    - 20gms 
Perungayam – Ferula asafoetida    - 10gms 
Palm Jaggery      - 1560gms 
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Method of Preparation 
 All the above  raw drugs are purified and powdered well.  Then the 
powder is grind with palm jaggery and is made into balls weighing 2 gms 
each. 
Dose 
 2 grams twice a day. 
Indications 
 Regulates the menstruation and induces  ovulation. 
Literature evidence 
 Nam Naatu Vaidhiyam - Kannapar  
 Page No.268 
Xkk; 
Botanical Name : Carum Copticum 
Rit - fhh;g;G jd;ik - ntg;gk;> gphpT - fhh;g;G. 
Fzk; 
  rPjRuq; fhrQ; nrhpahke; jk;nghUky; 
  Ngjpapiur; ry;fLg;G Nguhkk; - XjpUky;  
  gy;nyhLgy; %yk; gfkpitNeh nad;nrANkh? 
  nrhy;nyhLNghk; xknkdr; nrhy;.  (m.F) 
Chemical Constituents 
 Essential oil, Thymol 
rpj;jpu%y Nth;gl;il 
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Botanical Name : Plumbago Zeylanica 
Rit-fhh;g;G> tpWtpWg;G> jd;ik-ntg;gk;> gphpT-fhh;g;G 
Fzk; 
 fl;btpu zq;fpue;jp fhy;fs; miuahg;Gf; 
 fl;br;# nytPf;fq; fho;%yk; - Kl;buj;jf; 
 fl;L eP Nuw;wq; fdj;j ngUtapWk; 
 ml;Lq; nfhbNtyp ahk;. 
Chemical Constituents 
 Plumbagin. 
fLf;fha;j; Njhy; 
Botanical Name : Terminalia Chebula 
Rit - Kf;fpa Rit-Jth;g;G> mj;Jld; rpwpJ ,dpg;G> Gspg;G> fhh;g;G ifg;G 
ngw;wpUf;Fk;.  jd;ik-ntg;gk;> gphpT-,dpg;G 
Fzk; 
 jhil fOj;jf;fp jhY Fwpaptplg; 
 gPil rpypgjKw; NgjpKlk; - Milnal;lhj; 
 Jhykpb Gz;thj Nrhzpfh khiyapuz; 
 lhykpb Nghk;thpf;fh ahy;. 
Chemical Constituents 
  Tannin, Gallic acid, Chebulinic acid. 
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Nfh\;lk; 
Botanical Name : Costus Speciosus 
Rit - ifg;G> tpWtpWg;G> jd;ik-ntg;gk;> gphpT-fhh;g;G 
Fzk; 
 ehl;bYW ntl;il eLf;fk; vDNeha;fs; 
 Nfhl;lnkdr; nrhd;dhy; FiyAq;fhz; - $l;bw; 
 RuNjhle;  njhz;ilNeha; Njhyhj gpj;jk; 
 guNjrk; NghNk gwe;J. 
mhprpj; jpg;gpyp 
Botanical Name : Piper longum 
Rit - ,dpg;G> jd;ik-ntg;gk;> gphpT-,dpg;G. 
Fzk; 
 jpg;gpypapd; ez;LyQ; rpNyj;kj;ijg; Nghf;fptpLk; 
 cg;gprj;ij Nkfj;ij xl;Lq;fhz; - jg;ghky; 
 thj Rue;jzpf;Fk; khfgNuh fe;njhiyf;Fk; 
 jhJit tsh;g;gpf;FQ; rhw;W. 
Chemical Constituents 
 Resin, Volatile oil, Starch, Fatty oil, inorganic matter and an alkaloid, 
piperine. 
kpsF 
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Botanical Name : Piper nigrum 
Rit - ifg;G> fhh;g;G> jd;ik-ntg;gk;> gphpT-fhh;g;G 
Fzk; 
 NfhZfpd;w gf;ftyp Fa;aTNuh fk;thj 
 Nrhzpjq;f oj;jpw;Fs; Njhd;WNeha; - fhzhpa  
 fhJNeha; khjh;Fd;kq; fhkhiy ke;jnkd;wPh; 
 vJNeha; fhapUf;fpy; <q;F. 
 
 
Chemical Constituents 
 Piperine or Pipirine, Piperidine, Chavicin. 
Rf;F 
Botanical Name : Zingiber afficinale 
Rit - fhh;g;G> jd;ik-ntg;gk;> gphpT-fhh;g;G. 
Fzk; 
 #iyke;jk; neq;nrhpg;G NjhlNkg; gk;koiy 
 %yk; ,iug;gpUky; %f;FePh; - thyfg 
 Njhlkjp rhue; njhlh;thj Fd;kePh;j; 
 Njhlk;M kk;Nghf;FQ; Rf;F 
Chemical Constituents 
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 Camphene, Phellandrene, Zingiberine, Cincol, borneol, gingerol and an 
aleo-resin, gingerin.  
nrt;tpak; (Black Pepper Root) 
Botanical Name : Piper nigrum 
Fzk; 
 #iy mUrprd;dp njhy;ypUky; <isgpj;jk; 
 Nkiyf; Fuw;fk;ky; ntq;fsNeha; - %yRuk; 
 ft;tpaq;fj; NjW fdjh tutplKQ; 
 nrt;tpaq; nfhs;stpLe; Njh;. 
 
Chemical Constituents 
 A volatile alkoloid Piperine, piperidine, Chavicin. 
nfhj;jky;yp 
Botanical Name : Coriandrum Sativum 
Rit - fhh;g;G> jd;ik-rPjntg;gk;> gphpT-fhh;g;G. 
Fzk; 
 nfhj;jky;yp ntg;gk; Fsph;fha;r;ry; gpj;jke;jQ; 
 rh;j;jptpf;fy; jhfnkhL jhJel;lk; - fj;jpnaOk; 
 thj tpfhh;klh; td;fh;j;j gptpuzk; 
 g+jyj;jpy; yhjfw;Wk; Nghw;W. 
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Chemical Constituents 
 Coriandrol, d-pinene, 1-pinene, geraniol and baborneol. 
tha;tpsq;fk; 
Botanical Name : Embelia ribes 
Rit - ifg;G> jd;ik-ntg;gk;> gphpT-fhh;g;G. 
Fzk; 
 ghz;LFl;lk; Fd;kk; gUe;Jhy Neha;thje; 
 jPz;L jphptplQ; rpue;Jz;lk; - g+z;lkb 
 Neha;tpsq;ff; fhl;lhj Ez;fpUkp ahrdg;Gz; 
 tha;tpsq;;fq; fhl;l tpUkhh;. 
Chemical Constituents 
 Embelic acid, tannin, christembine alkaloid, Vidangin, Embelin. 
rPufk; 
Botanical Name : Cuminum Cyminum 
Rit - fhh;g;G> ,dpg;G> jd;ik-jl;gk;> gphpT-,dpg;G. 
Fzk; 
 thAnthL ehrpNeha; td;gpj;jQ; NruhJ 
 fhak; nefpohJ fz;FspUe; - Jhakyh;f; 
 fhusfg; ngz;kapNy! iffz;l jpj;jidAQ; 
 95
 rPufj;ij ePjpdKe; jpd;. 
Chemical Constituents 
 Cuminol, Cymene, Carvone. 
ngUq;fhak; 
Botanical Name : Ferula asafoetida 
Rit - ifg;G> fufug;G> jd;ik-ntg;gk;> gphpT-fhh;g;G  
Fzk; 
 je;jNt je;j %yj;njOk;gpzp 
  rUtfhsk; tpUr;rpfq;fPlk;kh 
 ke;jk;thjk; cjuth;j;jk; my;fpy;Neha; 
  khh;gzq; fl;l Fd;kk; kNfhjuk; 
 ce;Jnfh;g;gj;jpd; tpj;jpuQ;#iyr;#h; 
  cjpug;g+r;rp rpNyj;Jkj;JWk;typ 
 te;jnka;fLg; Nghbit Kw;WNk 
  khAehWew; fhaq;fpilf;fpNd;. 
Chemical Constituents 
 Organic Sulphur compound, Ferulic acid ester of asaresino-tannol, 
essential oil of garlic-allyl, persulphide and two turpenes. 
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ANNEXURE - II  
 
Qualitative analysis of Acidic/Basic radicals and phytochemical 
constituents in test drugs 
 
Procedure Observation inference 
Test for Calcium : 2 ml of extract 
is taken in a clean test tube. To 
this add 2 ml of  4% ammonium 
oxide solution.   
No white precipitate is formed Absence of calcium  
Test for Sulphate : 2 ml of the 
extract is added to 5 % barium 
chloride solution. 
No white precipitate is formed  Absence of Sulphate  
Test for Chloride : The extract is 
treated with Silver nitrate solution  
 No white precipitate is formed Absence of Chloride 
Test for carbonate : The 
substance is treated with Conc. 
HCl. 
No effervescence is formed  Absence of carbonate 
Test for Starch : The extract is 
added with weak iodine solution  
Blue colour is formed Presence of starch  
Test for Iron (Ferric) : The extract 
is treated with glacial acetic acid 
and potassium ferrocyanide  
No blue colour is formed Absence of Ferric iron 
Test for Iron (Ferrous) : The 
extract is treated with Conc. HNO3 
and ammonium thiocynate 
No Blood red colour is formed Absence of Ferrous iron 
Test for phosphate : The extract 
is treated with ammonium 
molybdate and conc. HNO3 
Yellow precipitate is formed Presence of phosphate 
Test for Tannic acid : The extract 
is treated with Ferric chloride  
Blue black precipitate is 
formed 
Presence of Tannic acid 
Test for Unsaturation : 1 ml of 
Potassium permanganate solution 
is added to the extract.    
Does not get decolourised  Absence of unsaturated 
compound 
Test for saponins: Dilute extract+ 
1ml of distilled water shake well. 
Froth formation Presence of saponins 
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Test for sugars :  
 Benedict method ; 5ml of  
Benedict solution heated gently 
then add 8 drops of diluted extract 
then heated in a boiling water bath. 
 
Molisch test; Dilute extract+2 
drops of Molisch+3ml conc.H2SO4. 
No colour change 
 
 
 
    
 
 No Reddish violet zones 
appeared 
Indicates the Absence of 
sugar 
 
 
 
 
Absence of carbohydrate 
Test for steroids : Liberman 
Burchard test ; Dilute extract +2 ml 
acetic anhydride+conc.H2SO4 . 
No Formation of red colour  Absence of steroids 
Test for amino acids: Dilute 
extract +2ml of Ninhydrin’s soln . 
Formation of  violet colour Presence of  amino acids 
Test for proteins: Biuret method ; 
1ml of dilute 
extract+1mlof5%CuSO4+ 
1%NaOH. 
Formation of Violet   colour Presence of proteins 
Test for Flavanoids : Dilute 
extract+ mg  bits+2drops of 
conc.HCl  and gently heated. 
No formation of pink colour Absence of Flavanoids 
Test for phenol; Dilute 
extract+2drops of FeCl3 soln. 
 Deep green colour is formed Presence of phenols 
Test for Tannins ; dilute extract 
+2ml of 10%lead acetate add. 
White precipitate formed Presence of tannins 
Test for alkaloids; 
 Mayer’s method;1ml of dilute 
extract + 1ml reagent. 
 
Dragendroff’s method; 1ml of dilute 
extract+ 1ml of reagent. 
 
Appearance of cream colour 
precipitate 
 
 
Appearance of orange colour 
precipitate 
 
Presence of alkaloids 
 
 
 
Presence of alkaloids 
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Table 1 
 
Preliminary acid, basic radicals and phytochemical screening 
S.No. Constituents MNT SVM 
1. Calcium + + 
2. Iron (Ferric) - - 
3. Iron (Ferrous) + + 
4. Sulphate + + 
5. Chloride + + 
6. Carbonate  + - 
7. Starch Trace - 
8. Phosphate + + 
9. Tannic acid + + 
10. Unsaturated - + 
11. Sugar + + 
12. Alkaloids + + 
13. Steroids Trace + 
14. Protein + + 
15. Tannins + + 
16. Phenols - + 
17. Flavanoids - - 
18. Saponins - - 
19. Amino acid + + 
20. Glycosides + + 
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Table 2 
 
 
Effect of Siddha Formulations (MNT  + SVM )  on Haematological 
parameters after 15 days repeated oral dosing (500 mg/kg) 
 
 
Groups Hb (gm/100ml) RBC (millions/cu.mm) 
Control 12.49±0.4113 5.20±1.047 
 
Test 
(500mg/kg. p.o.,) 
13.37±0.5164* 5.737± 2.033
* 
 
 
 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
*P<0.004 as compared with that of control. 
 
 
Table 3 
 
Effect of Siddha formulation (MNT  + SVM  ) on Biochemical markers of liver 
and kidney after 15 days repeated oral dosing (500 mg/kg/po) in rats 
 
 
Groups ALP (K.A.Units) 
AST 
(IU/L) 
SGOT 
ALT 
(IU/L) 
SGPT 
Urea 
(mg/100ml) 
BUN 
(mg/ 100ml) 
Control 4.973±0.3929 52.89±1.906 15.43±2.93 13.38±2.12 7.35± 0.84 
Test 
(500mg/kg. p.o.,) 
12.850±0.2074 *** 163.3±5.164 *** 76.75±0.88 *** 18.93±0.79 ns 8.12 ± 0.37ns 
 
 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
***P<0.001 as compared with that of control. 
ns – non significant when compared to control groups  
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Table 4 
 
Anti oxidant activity of (MNT  + SVM ) after 15 days  
repeated oral dosing (500 mg/kg) 
 
 
 
Groups 
 
LPO (n moles) GSH (n moles) 
Control 
 
0.59 ± 1.67 13.56 ± 0.632 
SVM 
(500mg/kg. p.o.,) 
0.29 ± 2.31*** 47. 56 ± 0.339*** 
 
 
 
N=6; Values are expressed as mean ± S.D followed by Student T- Test. 
***P<0.001 as compared with control.  
 
 
Table 5 
 
Effect of  (MNT  + SVM ) treatment in stress induced disturbance 
in estrous cycle in female rats 
 
Groups 
Oestrous cycle in days 
 
Dio 
estrous 
0 day 
Proestrous 
1st day 
Frank 
estrous 
2 nd day 
Frauk 
estrous 
3rd day 
 
Meta estrous 
4 th day 
Control group before 
stress 5/6 6/6 5/6 6/6 6/6 
Test group before stress 
(500mg/kg. p.o.,) 
6/6 5/6 4/6 6/6 6/6 
Control group after 
stress 6/6 0/6 0/6 0/6 0/6 
g Drug treated group 
after stress 
(500mg/kg. p.o.,) 
4/6 6/6 6/6 6/6 5/6 
 
 
Data show the number of animals (n=6) in each group showed different stages of oestrous 
cycle observed by vaginal cytology, starting from diestrous to metaestrous at 9 am on the 
days of examination.  
 
g  The drug treatment was given for 3 days prior to the induction of stress.   
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ANNEXURE - III 
 
Preclinical pharmacological & Toxicological 
studies of Maladu Neenga Thylam (MNT) and 
Saravalli Mathirai (SVM) on Estrous cycle  in 
experimental animals  
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1.0 MATERIALS AND METHODS 
 
1.1 Test Drugs 
 
 The following Therapeutic Siddha Medicines used in the study were 
processed by the methods prescribed in standard text books of siddha 
medicines. 
 
1.   Maladu Neenga Thailam (MNT) 
       MNT was prepared by the method described in Agathiyar  
       Kanagamani -100 P.No.34. 
 
2.  Saaravalli Mathirai (SVM)  
      SVM was prepared by the method described in Nam Naatu  
      Vaidhiyam P.No : 268) 
 
1.2 Preparation of drug for dosing 
 All drugs used for the study was suspended each time with 1% (w/v) 
solution of sodium carboxy methyl cellulose before administration. 
1.3 Drugs and chemicals 
 Fine chemicals used in these experiments were obtained from Sigma 
Chemicals company, U.S.A. Other analytical grade chemicals were obtained 
from S.d. Fine Chemicals Ltd., Mumbai. 
1.4 Experimental animals  
 Colony inbred animals strains of wistar rats of either sex weighing 200 - 
250 g and swiss albino mice of either sex (18-25 g) were used for the 
pharmacological and toxicological studies. The animals were kept under 
standard conditions 12:12 (day/night cycles) at 220C room temperature, in 
polypropylene cages. The animals were fed on standard pelleted diet 
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(Hindustan Lever Pvt Ltd., Bangalore) and tap water ad libitum. The animals 
were housed for one week in polypropylene cages prior to the experiments to 
acclimatize to laboratory conditions. The experimental protocol was approved 
by the Institutional Animal Ethical Committee (IAEC). 
1.5 Acute oral toxicity study     
Acute oral toxicity was conducted as per the OECD guidelines 
(Organization of Economic Cooperation and Development) 423 (Acute Toxic 
Class Method). The acute toxic class method is a stepwise procedure with 3 
animals of a single sex per step. Depending on the mortality and /or moribund 
status of the animals, on the average 2-4 steps may be necessary to allow 
judgment on the acute toxicity of the test substance. This procedure results in 
the use of a minimal number of animals while allowing for acceptable data 
based scientific conclusion. 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) 
and the results allow a substance to be ranked and classified according to the 
Globally Harmonized System (GHS) for the classification of chemicals which 
cause acute toxicity 
Wistar albino rats of either sex weighing 200-250 g were fasted 
overnight, but allowed water ad libitum. Since the formulation is relatively non 
toxic in clinical practice the highest dose of 2000 mg/kg/p.o (as per OECD 
guidelines “Unclassified”) was used in the acute toxicity study.   
The animals were observed closely for behavioural toxicity, if any by 
using FOB (Functional observation battery). 
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1.6 Repeated oral toxicity study  
Repeated oral toxicity studies can be used to get additional information 
regarding the toxicity profile of a chemical. Repeated oral toxicity studies are 
defined as those studies where the chemical is administered to the animal for 
a period covering approximately 10% of the expected life of the animal. 
Usually, the dose levels are lower than for acute studies and allow chemicals 
to accumulate in the body before lethality occurs, if the chemical possess this 
ability. 
Experimental procedure 
The following experimental procedure was followed to evaluate the 
repeated oral toxicity study of  
1. Maladu  Neenga Thylam (MNT) and Saravalli Mathirai (SVM). 
Group I    : Control animals received 1% Sodium carboxy methyl cellulose 
(CMC), 2   ml/kg/p.o. for 21 days  
Group II : Drugs suspended in CMC was given at the dose Level of 500 
mg/kg/p.o.  for 21 days 
 Body weight, food intake and water intake was recorded at two 
intervals with simultaneous observation for toxic manifestation and mortality, if 
any. At the end of 21 days treatment all the animals were sacrificed by over 
dosage of ether anaesthesia. Blood was collected and used for 
haematological studies. Section of liver, kidney, and heart were dissected out 
and kept in 10% formalin for histopathological studies. 
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1.7 Biochemical studies 
Aspartate aminotransferase (AST) 
 Aspartate aminotransferase was estimated using commercial AST kit 
(Span Diagnostics) by the method of Reitman and Frankel (1957). 
Alanine aminotransferase (ALT) 
 Alanine aminotransferase was estimated using commercial AST kit 
(Span Diagnostics) by the method of Reitman and Frankel (1957). 
Alkaline phosphatase (ALP) 
 Alkaline phosphatase was assayed using commercial ALP kit (Span 
Diagnostics)  by the method of King (1934). 
Urea   
 Urea was assayed using the commercial kit (Span Diagnostics) by the 
method of Coulambe  et al., (1965). 
1.8 Haematological studies 
Erythrocyte count 
 Erythocyte count was estimated by Hemocytometer method of Ghai 
(1995). 
Total Leukocyte Count (WBC) 
 Total Leukocyte Count was estimated by Hemocytometer method of 
John (1972). 
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Haemoglobin  
 Haemoglobin was estimated by method of Ghai (1995). 
1.9 Swimming  induced stress in irregularities of estrous cycle in rats 
Female rats (125-150 g) were randomized into groups of six animals 
each. Vaginal smear was taken at 9 am daily to evaluate the status of estrous 
cycle. Those animals showed the regular estrous cycle were selected for the 
study. The animals were divided into following groups and they received the 
respective regimen of treatment. 
 Group I - Control  
 ( n = 6) 
 Group II - Test drug   (KT + SVL, 500 mg/kg/p.o) 
 ( n = 6) 
The animals in Group I and II were given swimming stress for 30 mts in 
a vertical tub containing water upto 15 mm high maintained at room 
temperature. The vaginal smears of the stressed animals were examined for 
the stages of estrous cycle.   The animals showed the diestrous stage after 
the swimming test were given the test drug at the dose of 500 mg/kg/p.o for 3 
days and animals in the control group received vehicle only for same period. 
At the end of 3rd day after the drug/vehicle treatment the vaginal smears of all 
the animals were tested for the different stages of estrous cycle for the 4 
consecutive days. The same experiment is continued for 4 cycles after the 
induction of swimming stress as explained above        
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1.10 In Vivo Antioxidant study 
Samples of serum collected from  rats treated with test drugs were 
assayed for GSH (Moron et al , 1979)  and LPO (Yagi, 1976)  and the results 
were compared with  control group.  
2.0 Results 
2.1 Preliminary basic, acidic radicals and phytochemical studies   
The qualitative chemical analysis and acidic, basic radicals assay of 
the drugs showed the presence of phytoconstituents and minerals as depicted 
in (Table 1). 
2.2 Acute oral toxicity study 
MNT and SVM at the dose of 2000mg/kg/po did not exhibit any 
mortality in rats. As per OECD 423 guidelines the dose is said to be 
“Unclassified” under the toxicity scale. Hence further study with higher doses 
was not executed.  
2.3 Repeated oral toxicity for 21 days 
Test drug MNT and SVM at the dose of 500 mg/kg/po when 
administered orally for 21 days in rats did not show toxicity in renal functions. 
However the drug exhibited significant reduction in RBC count and elevation 
of marker enzyme levels of liver (Table 2 and 3). 
2.4 Antioxidant activity  
At the end of 21 days repeated oral toxicity study when the plasma of 
drug treated animals was examined for GSH activity, the level of GSH activity 
was increased significantly (p>0.001) in test groups (Table 4). 
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Results and Discussion 
Normal menstrual cycle in women is often disturbed by physical and 
mental stress. These changes in menstrual cycle may be attributed to 
psychological stress compounded by endocrine disturbances. Menstrual 
irregularities in women in reproductive age may also be attributed to the work 
environment, circardian changes precipitated by working in night shifts and 
odd hours of the day, life style etc. 
Irregular menstruation is regularized by siddha medicinal practitioners 
using herbo mineral preparations. Even these drugs are also used to treat 
clinical conditions like polycystic ovary. Though an model similar to human 
menstrual cycle cannot be developed in animals, stress induced changes in 
estrous cycle of rat can be used as a model to screen drugs which correct 
menstrual irregularities. The estrous cycle in rats will be completed in ¾ days 
and this will ease the cost and time of study for 5-6 cycles. The diestrous, 
proestrous, frank estrous and meta estrous can be identified by examining the 
vaginal cytology of rats. 
The swimming stress is an ideal model, can be taken for evaluating 
drugs acting on the regularization of estrous cycle in rats. 
In the present study all stressed rats uniformly showed diestrous phase 
of estrous cycle. The pretreatment with test drugs for 3 days before induction 
of swimming stress, helped to proceed the estrous cycle normally from 
diestrous to estrous, whereas the groups received no treatment were still on 
diestrous phase continuously for 3 cycles as evidenced by the vaginal 
cytology. 
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The exact mechanism of test drug that showed the reversal of 
irregularity on the estrous cycle of the rats after swimming test is not fully 
understood. The reversal of irregularity and maintenance of estrous cycle by 
drug treatment for another 3 consecutive cycles over untreated animals 
clearly establishes the positive correlation of results between clinical and 
experimental studies. Rat shows polyestrous, hence the results obtained from 
the rat study could be extrapolated to human study, is debatable. The 
hormonal profile of normal and stressed rats, before and after treatment and 
their reversal, if any, may give some more authentic data about the efficacy of 
drug in the treatment of menstrual irregularities in human beings. 
 The another important question to be answered on the efficacy of the 
drug treatment to prevent the irregularity of estrous cycle in 3-4 cycles is 
sustainable or not for a longer period or the drug treatment should be 
continued after a washout  period of 3-4 cycles to maintain the regular cycle 
on a sustained basis. 
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ANNEXURE - IV 
AN OPEN PILOT CLINICAL TRAIL OF SIDDHA DRUGS  MALADAU 
NEENGA THAILAM WITH SAARAVALLI MATHIRAI  FOR THE 
TREATMENT OF PENN MALADU (INFERTILITY) 
 
CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
I certify that I have disclosed all details about the study in the terms readily 
understood by the patient. 
 
 
Date       Signature 
 
 
       Name 
 
 
CONSENT  BY PATIENT 
 
 
I have  been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up 
including the laboratory investigations to be performed to monitor and 
safeguard my body functions. 
 
I am aware of my right to opt out of the trial at any time during the course of 
the trial without having to give the reasons for doing so. 
 
I, exercising my free power of choice, hereby give my consent to be included 
as a subject in the clinical trial of Siddha drugs Maladu Neenga Thailam with 
Saaravalli Mathirai  for the treatment of Penn Maladu. 
 
 
Date        Signature 
 
        Name 
 
 
Date        Signature of Witness 
 
        Name 
 
        Relationship 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47 
 
AN OPEN PILOT CLINICAL TRIAL OF SIDDHA DRUGS MALADU NEENGA 
THAILAM WITH SAARAVALLI MATHIRAI  FOR THE TREATMENT  OF  
PENN MALADU (FEMALE INFFERTILITY) 
 
 
FORM-I   SELECTION PROFORMA 
 
 
1. O.P.No:  ____________     2. Date :  ___________________    
 
3. S.No.________________     
 
4.  Name: ________________      Age (years):    _____________  
 
5.  Occupation _________________ 
 
6. Husband’s Name _____________    Age (years): ________________ 
 
7.  Address:  
 
  
 
                                                              
8.       Complaints and duration:  
 
 
 
MEDICAL HISTORY      Yes  No 
 
9. Tuberculosis 
 
10. Sexually  Transmitted Disease 
 
11. Pelvic Inflammatory Disease 
 
12. Diabetes Mellitus 
 
13. Chronic Illnesses 
 
14. Thyroid disorder  
  
15. HISTORY OF  NIPPLE DISCHARGE 
 
16. HISTORY OF VISUAL FIELD DEFECTS / HEADACHE  
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SURGICAL HISTORY      
 
17. Previous abdominal / pelvic surgery   Yes  No  
 
MENSTRUAL  HISTORY     Yes  No 
 
18. Age of menarche     _________ years 
 
19. Secondary amenorrhoea     Yes  No 
 
20. Cycle length      __________ days 
 
21. Duration of flow     ___________ days 
 
22. Quantity – No. of pads used 
 
23. Last Menstrual Period    ______________ 
 
24. Dysmenorrhoea     Yes  No 
 
25. Leucorrhoea      Yes  No 
 
MARITAL  HISTORY      
 
26. Duration  of  Marriage           Years 
 
27. Consanguinous     Yes  No 
 
SEXUAL   HISTORY      
 
28. Coital frequency       per week 
 
29. History of Dyspareunia    Yes  No  
 
30. History of Apareunia     Yes  No 
 
31. Loss of libido      Yes  No 
 
OBSTETRIC  HISTORY      
 
32. No. of live children if any    ____________________ 
 
33. No. of Spontaneous abortions if any   ____________________ 
 
34. No. of induced abortions if any   ____________________ 
 
 
OCCUPATIONAL  HISTORY     
 
35. Working in night shifts   Yes  No 
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PERSONAL HABITS                                           
 
36. Diet habits     Veg  Non Veg 
 
37. Bowel habits  
 Constipation     Yes  No 
 
38. FAMILY HISTORY    Yes  No 
 
39. History of Previous Investigations if any: 
 ________________________________ 
 
GENERAL EXAMINATION  
 
40. Physical built   Obese   Normal 
 
     BMI 
  
41.  Body Weight (kg):                                                    
 
42. Height (cm) 
 
43.  Temperature (°F):      
 
44.  Pulse rate / minute:                                          
 
45.  Heart rate / minute:        
 
46.  Respiratory rate / minute:                              
   
47.  Blood pressure (mmHg):                                
                                                        Yes                       No            
 
48.  Pallor:                                 
 
49.  Jaundice:                       
 
50.  Cyanosis:  
           
51.  Lymphadenopathy:  
  
52.  Pedal oedema:  
  
53.  Clubbing:                                
 
54.  Jugular vein pulsation:            
 
55.  Congenital Abnormalities     
 
56.  Goitre 
 
57.  Hirsutism 
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58. Tracheal deviation 
 
59. Development of axillary and pubic hair 
 
60. Breasts      Normal        under development   
 
 
    
EXAMINATION OF VITAL ORGANS  
        Normal   affected 
 
61. Heart 
 
62. Lung 
 
63. Liver 
 
64. Spleen 
 
SYSTEMIC EXAMINATION 
 
65. Per speculum Examination 
 
66. Bimanual Pelvic examination 
 
 Palpation of the uterus 
 
 Palpation of the uterine appendages 
 
 The pouch of Douglas 
      Normal   affected 
67. Heart 
 
 
SIDDHA SYSTEM OF EXAMINATONS 
 
 
68. THINAI 
 
      1. Kurunji           2. Mullai                3. Marutham     
 
      4. Neithal                5. Palai 
      
  
69. GUNAM 
 
    1. Sathuva gunam                  2. Rajo gunam         
 
    3. Thamo gunam 
IYMPORIKAL  
                                      1. Normal        2. Affected 
  
70. Mei                         _ ____________________ 
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71. Vaai                          ______________________ 
 
72. Kan              _____________________ 
 
73. Mookku                        _____________________ 
 
74. Sevi                                   _____________________ 
    
    
 KANMENTHIRIUM  
   
  
75. Kai                      _____________________ 
 
76. Kaal          _____________________ 
 
77. Vaai          _____________________ 
 
78. Eruvai          ____________________ 
 
79. Karuvaai          _____________________ 
 
 
                                                                                                                         
UYIR THATHUKKAL 
      
VALI 
    
                                        1. Normal       2. Affected 
 
80. Pranan                                       ____________________ 
 
81. Abanan                                  __  ___________________ 
 
82. Samanan                                         ____________________ 
 
83. Udhanan                                        _____________________ 
 
84. Viyanan                                        _____________________ 
 
85. Nagan                                        _____________________ 
 
86. Koorman                                        ____________________ 
 
87. Kirukaran                                      _____________________ 
 
88. Devathathan                                   ______________________ 
 
89. Tananjeyan               _____________________ 
AZHAL 
                                     1. Normal          2. Affected 
 
90. Anala pittham            _____________________ 
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91. Prasaka pittham                _____________________ 
 
92. Ranjaka pittham                       ______________________ 
 
93. Aalosaka pittham                                 ______________________ 
 
94. Saathaka pittham                               ______________________  
      
 
IYAM 
                                     1. Normal          2. Affected                                     
 
95. Avalambagam            ______________________ 
 
 
96. Kilethagam                                                       _______________________  
 
97. Pothagam                        ______________________ 
 
98. Tharpagam                       _______________________     
 
99. Santhigam                        ______________________ 
 
        
 UDAL THATHUKKAL 
                                     
      1. Normal         2. Affected 
100. Saaram                  _______________________ 
 
101. Chenneer                                                      _______________________ 
       
102. Oon                                       _____________________ 
 
103. Kozhuppu                          _______________________ 
   
104. Enbu                        __ _____________________ 
     
105. Moolai                                       _    ______________________ 
 
106. Suronitham                      _______________________ 
            
  
ENVAGAI THERVUKAL 
 
                              1. Normal        2. Affected 
107. Naa                                          _____________________ 
 
108. Niram                                     _____________________ 
 
109. Mozhi                                      _____________________ 
 
110. Vizhi                                       ______________________   
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111.    Sparisam:    1.Mithaveppam         2.Miguveppam         
                    
        3. Thatpam 
 
 Malam        1. Normal        2. Affected    
 
112. Niram                       
 
113. Nurai 
 
114. Karumai  
                                                  
115. Kalappu  
                     
116. Thanmai                      
    
Moothiram    
        
Neerkuri   
 
117. Niram                         ______________________ 
     
118. Eadai                                          _____________________ 
                                
119. Manam                       ______________________  
 
120. Nurai                                 ______________________ 
 
121. Enjal                                  ______________________ 
  
 
122. Neikuri:       1.Vatham          2. Pittham         3. Kapham      
     
        
123. Naadi:    1.Vatham         2.Pittham                  3.khabam        
    
     4. Vathapittham             5. Vathakhabam            6. Pitthavatham   
  
     7. Pitthakhabam            8. Khabavatham            9. Khabapittham    
  
INVESTIGATIONS 
        
BLOOD 
 
124. TC (cells /cumm): 
 
125. DC (%):         P P   E              L       B             E     B 
 
       M                       
 
 
126. Hb (gm %):                  . 
 
        ESR (mm/hr):        117. 1/2hr                     118.1hr 
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127. Blood Sugar (F) (mg %): 
 
128. Post Prandial (mg %): 
 
129. Random (mg %) 
 
130. Blood Urea (mg %):     
 
131. Serum Creatinine (mg %):              .  . 
  
132. Serum Cholesterol (mg %): 
 
133. VD RL  Reactive  Non Reactive    
 
134.  FSH  LH   Prolactin   TSH 
 
 URINE 
 
135. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
    4. + + +    
                                                                                                                                                                 
136. Sugar (F):          0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
 
137. Sugar (PP):        0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
         
Deposit                                1. Yes          2. No 
 
138. Pus cells                       
 
139. Epithelial cells             
 
140. RBC                               
 
141. Crystals                             
  
142. ULTRA SOUND 
 
 
143. ADMITTED TO TRIAL:     1.Yes                   2. No   
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If yes   
 
144. S. No:    
                 
145. O.P   No.     
 
146. Drug issued     (g): 
 
 
 
 
 
Station                                                                                            
 
Date:                                                                                        Signature of the doctor 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI-47 
 
AN OPEN PILOT CLINICAL TRIAL OF SIDDHA DRUGS MALADU NEENGA 
THAILAM WITH SAARAVALLI MATHIRAI  FOR THE TREATMENT  OF  
PENN MALADU (FEMALE INFFERTILITY) 
 
FORM-II ASSESSMENT PROFORMA 
 
1. O.P.No  ______________   2. S.No: ________    
 
3. Name: _______________________________  4. Age____________ 
 
5.Date of the Assessment  
 
6.Day of Assessment  
 
 
CLINICAL ASSESSMENT 
 
       1. Yes                  2.No 
 
7. Oligomenorrhoea  
 
9. Amenorrhoea 
 
10. Regular Periods 
    
11. Hypomenorrhoea 
  
12. Pain during menstruation 
 
13. Date of Menstruation  
    
14. Naddi  
  
 
INVESTIGATIONS: (after  treatment) 
 
15. Mid luteal phase progesterone  estimation 
 
16.  Ultrasound – Follicular study 
 
17.  Urine for gravidex 
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18.       DRUGS ISSUED           1. No. of  tablets                2. Volume of Thylam   
                
19.     DRUGS RETURNED     1. No. of tablets                 2. Volume of Thylam 
 
 
 
 
Date  
 
Station                                                                                  Signature of  the doctor 
 
 
 
RESULT          Ovulation / Fertility           Failure 
                  
 
 
 
 
Date:     
                                                                                            Signature of the Doctor  
Station: 
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